NAME: DAVID WILLIAM GRAINGER

Department of Biomedical Engineering, and Affiliation: Department of Pharmaceutics and Pharmaceutical University of Utah University Distinguished Professor, Chair, Title: Biomedical Engineering Chemistry, Biomaterials Science, Surface Specialty: Chemistry TEL:

Address: Salt Lake City, UT 84112-5820 USA

e-mail: [email protected] Email: http://www.bioen.utah.edu/faculty/DWG/

PERSONAL: born June 11, 1961; married (Holly), four children (Nat, Jessie, Maddy, Eliza)

EDUCATION: 1987 Ph.D., Pharmaceutical Chemistry. University of Utah, Salt Lake City, UT Major areas of study: , Biomaterials Science, Surface Chemistry

1983 B.A., Engineering, Chemistry minor. , , NH

1979 Valedictorian, Lewis and Clark High School, Spokane, WA

[Google Scholar H-index = 58; ~11,870 total citations (August 2018)]

DISTINCTIONS

 Council Member, National Institute of Biomedical Imaging and Bioengineering, NIH, 2017-present.  Invited Tsinghua Xuetang Fellow Lecture, “Chemistry Impacts and Challenges in Modern Medical Technology,” Department of Chemistry, Tsinghua University, , , December 5, 2017.  Chair, External Advisory Board, EPSRC Next Generation Biomaterials Programme, University of Nottingham, U.K., 2017-present  Chair, AO Foundation Research Review Committee, AO Foundation, Switzerland, 2017-present.  Member, Scientific Advisory Committee, Centre for Research in Medical Devices (CÚ RAM), National University of Ireland, Galway, Ireland, 2016-present.  2016 Fulbright Senior Scholar (Univ. Otago, New Zealand), February-June, 2016  Honorary William Evans Visiting Faculty Fellow, University of Otago, New Zealand, 2015  Named “Dr. K.T. Dholakia” prize oration, “Challenges in translating antimicrobial technologies to orthopedic implants”, Bombay Orthopedic Society’s Western India Regional Orthopedic Conference, Mumbai, India, December 28, 2014.  The 58th Annual Edward T. Smith Orthopaedic Invited Lectureship, “Biologics for Orthopaedics – Where Are We in 2014 and the Future?”, University of Texas-Houston, Department of Orthopaedic Surgery, November 14, 2014.  Member, Helmholtz Association Invited Research Center Evaluation Team (Biointerfaces), Karlsruhe, Germany, March 2014  Excellence in Surface Science Award, Surfaces in Biomaterials Foundation, 2013  Named “University Distinguished Professor”, University of Utah, 2012-present  Member, Scientific Advisory Board, Univ. Wisconsin NSF MRSEC “Nanostructured Interfaces”, 2006-present  Member, Board of Directors, Utah-Inha Joint Center for Research in Drug Delivery Systems, Song-do, Korea, 2009-2017  Elected Fellow, Entrepreneurial Faculty Scholars, University of Utah, 2011-present  Elected Member, Academic Council, AO Foundation, Davos, Switzerland, 2004-2013 (international orthopedic not-for-profit research foundation)  18th Annual Roland D. Annual Pinkham Lecture “Nanotechnology in ”, Swedish Hospital Foundation, Seattle, WA, 2004  Member, Academic Circle of Experts (ACE), Defense Intelligence Agency’s Biochem20/20 advisory group, Washington, DC; 2004-2013.  International Advisory Board, EMPA (Swiss National Metrology Research Institute), St. Gallen, Switzerland, 2010-2014  Scientific Advisory Board, Tissue Engineering for Drug Development, Switzerland, 2012-2016.  Scientific Advisory Board, Berlin-Brandenburg Center for Regenerative (BCRT), Charité-Berlin, Germany, 2008-2016.  Advisory Board, Entrepreneurial Faculty Scholars, University of Utah, 2011-2016  Member, Advanced Scientific Institute Advisory Council, RIKEN Institute (Japan), May, 2011.  Scientific Advisory Board, Julius Wolff Research Institute, Charité-Berlin, Germany, 2008-2011.  Member, KoF11 Quality-Renewal Expert Review Panel, Uppsala University, Faculty of 5-year performance review, May, 2011.  University of Utah Distinguished Graduate and Post Doctoral Scholar Mentor Award, 2010  Co-chair, International Symposium on Recent Advances in Drug Delivery Systems, 2006-present  Chair, International Advisory Board, Swiss Competence Center for Materials Excellence, 2006-09  Chair, International Advisory Board, Swiss Materials Center, MATLIFE, 2006-2011  Chair, CRS Nagai Award Committee, Controlled Release Society, 2005-2011  Scientific Advisory Board, Willem S. Kolff Institute, University of Groningen, The Netherlands, 2004-2010.  Member, International Scientific Evaluation Committee, AsMeW Research Center, Waseda University, Japan, 2006-09  EU Madame Curie guest lectures, Technical University-, Germany, 2009  Technical advisor to Utah’s Pierre Lassonde New Venture Development Center student team’s Grand Prize, 2009 Carnegie Mellon McGinnis Venture Competition (one the nation’s premier new venture competitions) using Grainger intellectual property.  Elected Fellow, America Association for the Advancement of Science (AAAS), 2008  15th Annual Fritz Straumann lecture, AO Foundation, Davos, Switzerland, December, 2008.  Inducted Honorary Fellow, International Union of the Societies of Biomaterials Science and Engineering, 2008  Clemson Award for Basic Research in Biomaterials, Society for Biomaterials, 2007  Chair, AVS Biomaterials Interfaces Division, AVS (Surface Science Society), 2007-2008  Clemson Invited Professor, Clemson University, April, 2006  International Scientific Programming Committee, Tissue Engineering and Regenerative Medicine International Society annual meeting, 2003-2008  Nominated, Teacher of the Year, College of Pharmacy, University of Utah, 2007  Inducted Fellow, American Institute of Medical and Bioengineering (top 2% of bioengineers), 2000  Scientific Advisory Board, NESAC/Bio NIH Research Resource, Surface Analysis, 2001-2009  Chair, NIH Heart, Lung and Blood Institute Advisory panel on “Nanotechnology in Blood”, 2006  Outstanding Faculty Member, CSU Greek Life & Interfraternity & Panhellenic Council, 2006  AVS Biomaterials Interface Division Program Chair, 53rd International AVS Symposium, 2006  Nominated, “Gladys Eddy Colorado State University Teaching Award”, 2005.  Co-chair, National Cancer Institute U54 Nanotechnology Cancer Center Review Panel, 2005  Member, NIH Surgery and Bioengineering Study Section, 2000-2005  Chair, NIH P41 Research Resource Review panels, 2003, 2004, 2005  Ad hoc reviewer: National Institutes of Health EBT, GDD, ZRG review panels, 2000-present  PhRMA Foundation “Excellence in Pharmaceutics” Award, 2005  Board of Scientific Advisors, Controlled Release Society, 2003-2006  Scientific Program Chair, Controlled Release Society, 31st Annual Symposium, 2004  18th Annual Roland D. Annual Pinkham Lecture “Nanotechnology in medicine”, Swedish Hospital Foundation, Seattle, WA, 2004  Outstanding Teacher Award, Students as Leaders in Science, Colorado State University, 2004  Colorado State University Alumni Association "Teacher of the Year", 2003  Elected, Who’s Who in Science Education, 2003  Session Organizer, NIH BECON Symposium (Sensor Biocompatibility), July 2002  Chair, NASA Biomaterials in Deep Space review panel, March 2002  Chairperson, Gordon Conference on Biomaterials, Biocompatibility and Tissue Engineering, 2001  USWest/Qwest Faculty Education Excellence Award, Colorado State University, 2000  Colorado State University College of Natural Sciences "Undergraduate Teacher of the Year", 2000  Top Ten Finalist, Colorado State University Alumni Association "Teacher of the Year", 2000  Vice-Chair, Gordon Research Conference on Molecular Recognition, 1999  DuPont Research Fellowship, 1997-98  DuPont Plunkett Fellowship for Innovations with Fluoropolymers, 1996  3M Faculty Fellowship, 1996-98  National Science Foundation Young Investigator Award, 1993-1998  Chair, Biomolecular Engineering Special Interest Group, Society for Biomaterials, 1996-98  Council Member, Society for Biomaterials, 1993-1999  Merck Academic Fellow Award, 1991-92  Alexander von Humboldt Foundation Postdoctoral Fellowship Award, Institute of Organic Chemistry, University of Mainz, Germany, April 1988-October 1989  Pharmaceutical Manufacturers' Association Predoctoral Fellowship, July 1987  Osco/Skaggs Pharmaceutical Research Fellowship, University of Utah, July 1986  Biomedical Research Fellowship, Twente University of Technology, The Netherlands, 1986.  Student Research Award, Society for Biomaterials, June 1986  Bausch & Lomb Honorary Science Award, May, 1979

PROFESSIONAL EXPERIENCE

 Chair, Department of Biomedical Engineering, University of Utah, 2017-present.  University Distinguished Professor, University of Utah, 2008-present  University Distinguished Professor, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, 2006-present.  University Distinguished Professor, Department of Biomedical Engineering, University of Utah, 2006-present  Adjunct Professor of Chemistry, University of Utah, 2007-present.  Visiting Professor, Keio University, Tokyo, Japan, 2017-present.  George D. and Dolores Doré Eccles Presidential Endowed Chair in Pharmaceutics and Pharmaceutical Chemistry, Health Sciences, College of Pharmacy, University of Utah, 2006-2016.  Professor, Department of Chemistry, Colorado State University, Ft. Collins, CO 1999-2006.  Associate Professor of Chemistry, Colorado State University, Ft. Collins, CO 1994-1999.  President and Chief Scientific Officer, Gamma-A Technologies, Inc. (anti-microbial delivery biotech start-up), Herndon, VA, 1998-1999.  Invited Professor, CNRS Laboratiore Biomaterieux aux Polymeres, Univ. Paris XIII (Prof. V. Migonney), Sept.-Oct., 1997, April-May, 2003, July, 2004, Summer, 2005.  Invited Professor, JSPS Fellow, Institute for Biomedical Engineering, Tokyo Women's Medical University, Tokyo, Japan (Prof. Teruo Okano), Oct.-Dec., 1997.  Associate Professor of Chemistry: Department of Chemistry, and Molecular , Oregon Graduate Institute of Science & Technology, Portland, OR, August 1993-June 1994.  Assistant Professor of Chemistry: Department of Chemical and Biological Sciences, Oregon Graduate Institute of Science & Technology, Portland, OR, November 1989-July 1993: Graduate-level teaching and research.  Humboldt Postdoctoral Research Fellow: Institute for Organic Chemistry, University of Mainz, Germany, April 1988-November 1989: Biomembrane surface recognition, -membrane interactions, polymerizable mono- and bilayer membranes, properties of ultrathin films and molecular monolayers. Prof. Helmut Ringsdorf, supervisor.  Postdoctoral Research Fellow: Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT, September 1987-March 1988: Novel polymeric materials for surface-active, controlled-release and stimuli-sensitive pharmaceutical devices. Prof. S. W. Kim, supervisor.  Doctoral Study: Department of Pharmaceutics, University of Utah, Salt Lake City, UT, September 1983-September 1987: Synthesis and characterization of multiblock amphiphilic block copolymers for use as model surfaces for investigating polymer interfacial interactions with blood. Prof. S. W. Kim and Prof. Teruo Okano, supervisors.

MEMBERSHIP IN PROFESSIONAL SOCIETIES: American Institute of Medical and Biological Engineers (Fellow), AVS (Surface Science Society), American Chemical Society (Polymer Science, Colloid and Surface Chemistry Divisions), Controlled Release Society, Society for Biomaterials, AAAS, Alexander von Humboldt Foundation Society, American Association of Pharmaceutical Scientists

SCIENTIFIC PEER REVIEWER FOR:  Chair, National Cancer Institute “Formulating Natural Products with Nanotechnologies” review panel, November, 2015.  Panel member, proposal review, Juvenile Diabetes Research Foundation, February 2016  Member, 7-year Performance review evaluation, Department of Pharmacology, School of Medical Sciences, University of Otago, New Zealand, November, 2015.  Academic Content Review Panel, Peking Union Medical College, Beijing, China, August, 2015.  FORMAMP FP-7 EU research project on antimicrobial peptides (Sweden-centered) (2014-15)  Co-chair, NIBIB QUANTUM program: TECHNOLOGICAL INNOVATION TO SOLVE A MAJOR MEDICAL OR PUBLIC HEALTH CHALLENGE (U01) Panel Review, June, 2015.  Chair, NIH-CSR Blue Ribbon Advisory Panel for “Assessing Bioengineering/Computational Biology study sections”, April, 2015.  Reviewer, NIH Director’s Early Independence Award (DP5), April, 2015.  Chair, National Cancer Institute “Special Nanotechnologies in Cancer Drug Delivery” review panel, February, 2015.  National Science Foundation biomaterials review panel BMAT, 2013-14.  Swiss AO Foundation Research Fund and Research Commission 2006-present  German Helmholtz Association, BIFTM Center review panel member, 2014.  Estonian Research Foundation reviews, 2013-14.  Defense Threat Reduction Agency (DTRA, USA), 2012, 2013, 2014.  Former Chair and Standing member, “Emerging Bioanalytical & Imaging Technologies” National Institutes of Health CSR scientific review group (SRG), 2008-2012.  Invited expert, NIH RC-1 Challenge grant ARRA expert review panel, July, 2009.  RIKEN National Research Institute, (on-site evaluation), Japan, 2009, 2010, 2011.  Luxembourg FNR proposal reviews (mail in), 2010, 2011  Swiss National Science Foundation (mail-in), SNF (2008-2010)  Dutch National Science Foundation NWO (mail-in), (2010)  Swedish National Science Foundation (mail-in), (2009)  European Union Project proposal reviewer, 2008-present, including on-site Chair, Drug Delivery panel (Brussels), 2007, and mail-in reviews annually.  Chair, NIH Heart, Lung and Blood Institute Advisory panel on “Nanotechnology in Blood”, 2006  Co-Chair, U54 panel review for Centers in Nanotechnology Cancer Therapeutics, 2005  Standing member, NIH Surgery and Bioengineering Study Section (SB, 2000-2005)  National Institutes of Health Research Resource P41 Site Reviews: annually 2005-2008  Reviewer, National Institutes of Health Special Emphasis Panels: Mail-in reviewer for RC-4 ARRA Challenge Grants, June, 2010; ZRG1 SBIB-E 02 M (Chair, 3/2010), Invited Expert for RC-1 Challenge Grant Review Panel (7/2009), Enabling Bioanalytical Technologies (EBT), 2006; Advanced Wound Healing Centers (ZRG), 2006, Gene and Drug Delivery (GDD), 2003-2005; Biomedical Research Partnerships (BRP ZRG), 2004; “In vivo Biosensors” (ZRG), 2003  NIST Center for Neutron Research (NCNR) 2004-2007  Research Corporation (Tucson, AZ), 2000-present  ACS Petroleum Research Foundation, 1996-present  NSERC (Canada) Research grants (2003-2016)  National Science Foundation (MRSEC program 1998-2001; other individual proposals 1997-present)  Singapore A-Star Program, Tissue Engineering, 2004-2006

Scientific Editorial experience (Journals): Biomaterials (Associate and Handling Editor, 1998-2016) IF 8.3 Journal of Controlled Release (editorial board, IF 7.7) Advanced Drug Delivery Reviews (editorial board, special issue editor, IF 15.04) Journal of Biomedical Materials Research (editorial board, IF 3.4) Journal of Biomaterials Science Polym. Ed., (editorial board member, IF 2.31), European Cells and Materials (editorial board member, IF 6.03)

Special issue editors: 1. D.W. Grainger, T. Okano, Theme Editors, “Biomedical Micro- and Nano-Technology”, Adv. Drug Del. Rev., Volume 55:3 (2003). (one of the most highly downloaded ADDR volumes to date). 2. D.W. Grainger, Theme Editor, “Nanotoxicity in Drug Delivery”, Adv. Drug Del. Rev., Volume 61:6 (2009). 3. D.W. Grainger, Theme Editor, “Drug Delivery to Bone”, Adv. Drug Del. Rev., Volume 64 (2012). 4. M. Textor, U. Graf, M. Lutolf, K. Maniura, J. Kelm, D.W. Grainger, Theme Editors, “Innovative tissue models for in vitro drug development”, Adv. Drug Del. Rev., Volume 69-70 (2014). 5. T. Deans, M. Fussenegger, D.W. Grainger, Theme Co-Editors, “Synthetic Biology and Drug Delivery”, Adv. Drug Del. Rev., (2016).

Book editor:  Co-editor, Comprehensive Biomaterials II (325 chapters, 7 volumes, Elsevier, Amsterdam, on-line, largest comprehensive biomaterials compendium ever published, eBook ISBN: 9780081006924; Hardcover ISBN: 9780081006917, 2017). pp. 4858.  Co-editor, Comprehensive Biomaterials (253 chapters, 6 volumes, Elsevier, Amsterdam, on-line, largest comprehensive biomaterials compendium ever published, publication date, 2011). pp. 3672.  Co-editor, Fluorinated surfaces, coatings and films, ACS Press, Washington, DC, 2001, pp. 246.

Regular journal peer-reviewer for: Proc. Natl Acad. Science, Science Translational Medicine, , Nature Materials, Nature Nanotechnology, J. American Chemical Soc., Advanced Materials, many others **(over 55 original scientific manuscripts reviewed annually since 1995) *”Reviewer of the Year” recognition: Acta Biomateriala, 2011

Other professional service: Controlled Release Society: Board of Advisors (1994-1996): Fellowship Award Committee Chair (2002-2006); International Symposium organizing committee chair (2004) Society for Biomaterials: Special Interest Group Inaugural Chair ( and Cells at Interfaces); Awards committee (2017-present)

Scientific Symposia Organization: (28 international symposia organized to date)

 Co-organizer, Discussion leader, 7th Thesinge Biofilms Conference, Groningen, The Netherlands, October, 2018.  Co-organizer, Session Chair, Panel Member, Biointerface International, Zürich, Switzerland, September, 2016.  Co-organizer, Session Chair, Translate! 2016 conference, Berlin, Germany, May, 2016  Co-organizer, Discussion leader, 6th Thesinge Biofilms Conference, Groningen, The Netherlands, September, 2016.  Co-organizer, Session Chair, Translate! 2014 conference, Berlin, Germany, May, 2014  Co-organizer, Session Chair, 17th International Symposium on Recent Advances in Drug Delivery Systems, 2014.  Co-organizer, Discussion leader, 5th Thesinge Biofilms Conference, Groningen, The Netherlands, September, 2014.  Co-organizer, Discussion leader, 4th Thesinge Biofilms Conference, Groningen, The Netherlands, September, 2012.  Co-organizer, Session Chair, 16th International Symposium on Recent Advances in Drug Delivery Systems, 2012.  Discussion leader, 2011 Gordon Research Conference on Biomaterials and Biocompatibility, Holderness, NH.  Co-organizer, Discussion leader, 3rd Thesinge Biofilms Conference, Groningen, The Netherlands, September, 2010.  Co-organizer, Session Chair, 15th International Symposium on Recent Advances in Drug Delivery Systems, 2010.  Discussion leader (Biofilms), Gordon Research Conference, Biointerface Science, Les Diablerets, Switzerland, October, 2006, and September, 2010.  Organizing Committee, NanoBio-Zurich, Zurich, Switzerland, August, 2010.  Co-organizer, “Microarray Grand Challenges Mini-symposium”, AVS 56th International Technical Program, San Jose, CA, November, 2009.  Co-organizer, Thesinge Biofilms Conference, Thesinge, The Netherlands, 2008 and 2010.  Co-chair, 14th International Symposium on Recent Advances in Drug Delivery Systems, 2009.  Co-chair, 13th International Symposium on Recent Advances in Drug Delivery Systems, 2007.  Chair, AVS BioFOCUS Technical program, 55th AVS International Symposium, Boston, 2008.  Chair, AVS Biomaterials Interface Division Technical Program, 53rd International AVS Symposium, San Francisco, CA, 2006.  Scientific Organizing Committee and Session Chair, Regenerate Symposium (formerly ‘Tissue Engineering’), 2003, 2004, 2005, 2006.  Scientific Organizing Committee and Session Chair, BioSURF Symposium, Zurich, Switzerland, 2001, 2003, 2005, 2007.  Scientific Organizing Committee, in Orthopedic Repair Symposium, Lausanne, Switzerland, 2006, 2007, 2008.  Chair, AVS Biomaterials Division “DNA at Surfaces” Symposium, Boston, MA, 2005  AVS Biomaterials Interface Division Program Committee member, 2001-present  Scientific Program Chair, Controlled Release Society, 31st Annual Symposium, Honolulu, HI, 2004  Session organizer, Controlled Release in orthopedic applications, Controlled Release Society Annual Symposium, Seoul, Korea, 2002.  Session Organizer, NIH BECON Symposium (Sensor Biocompatibility), July 2002  Chairperson, Gordon Conference on Biomaterials, Biocompatibility and Tissue Engineering, 2001.  Symposium Co-organizer, ACS POLY Symposium, “Polymer Bioconjugates,” American Chemical Society National Meeting, San Francisco, CA, March 26-30, 2000.  Vice-Chair, Gordon Research Conference on Molecular Recognition, 1999.  Symposium Co-organizer, ACS POLY Symposium, “Fluorinated Surfaces, Coatings and Films, American Chemical Society National Meeting, Boston, 1998.  Symposium Co-organizer, ACS POLY Workshop: “Contemporary Biomaterials Through Precise Control of Macromolecular Chemistry and Architecture,” Williamsburg, VA, November 19-22, 1998.

International Student Supervisory Committees: 1. Wei-Chiang Shen, Department of Chemical Engineering, University of Toronto, Canada (Prof. Molly Shoichet, 2001) 2. Martin Halter, Department of , ETH-Zurich, Switzerland (Prof. Marcus Textor, 2008) 3. Bonnie Leung, Department of , McMaster University, Canada (Prof. Adam Hitchcock, 2010) 4. Isabel Saldarriaga Fernández, Department of Biomedical Engineering, Royal University of Groningen, The Netherlands (Prof. Henk Busscher, 2010) 5. Gurru Sobbhiadis, Department of Biomedical Engineering, Royal University of Groningen, The Netherlands (Prof. Henny van der Mei, 2010) 6. Gurvinder Singh, Faculty of Science, University of Aarhus, Denmark (Prof. Peter Kingshott, 2010) 7. Edgar Wakelin, Dept. of Physics, University of Sydney, Australia (Prof. Marcela Bilek, 2016). 8. Chris Sarsons, Biomedical Engineering program, University of Calgary, Canada (Prof. Tina Rinker), 2016. 9. Jessica A Lyndon, Department of Materials Science, Monash University, (Prof. Ben Boyd) “Magnesium alloys as bioresorbable biomaterials with drug delivery capabilities”, 2017.

AREAS OF RESEARCH EXPERTISE: Surface Modification, Patterning and Analytical Methods, Protein Immobilization and Release, Ultrathin Protein and Polymer Films, Drug Delivery, Combination Medical Devices, Biomaterials, Nanotoxicology, Diagnostic and Microarray Surfaces, Tissue Engineering, Protein-, Bacteria-, and Cell-Surface Interactions, Biotechnology, Colloids, Fluorinated Surface Chemistry, Membrane biophysics.

Didactic Courses taught: Biomaterials (graduate), Physical Chemistry of Pharmaceutical Systems (graduate), General Chemistry (undergraduate), Polymer chemistry (Graduate), Analytical chemistry (undergraduate), Membrane biophysics (graduate), Surface chemistry (graduate)

PEER-REVIEWED RESEARCH PUBLICATIONS:

1. D. W. Grainger, T. Okano and S.W. Kim, "Surface Characteristics of Polyethylene Oxide-Polystyrene Multiblock Copolymers", in ACS Advances in Biomedical , C.G. Gebelein, Ed., Plenum, NY, pp. 229-247, (1987). 2. C. Nojiri, T. Okano, D. W. Grainger, K.D. Park, S. Nakahama, K. Suzuki and S.W. Kim, "Evaluation of Nonthrombogenic Polymers in a New Rabbit A-A Shunt Model", Trans. ASAIO, 10(3) 596-601 (1987). 3. D.W. Grainger, S.W. Kim, J. Feijen, “Poly(dimethylsiloxane)-poly(ethylene oxide)-heparin block copolymers I, Synthesis and characterization”. J Biomed Mater Res., 22(3):231-49. PubMed PMID: 3360815, (1988). 4. T. Okano, D. W. Grainger, K.D. Park, C. Nojiri, J. Feijen and S. W. Kim, "Improved Blood Compatibility of Heparin Immobilization and PEO-PDMS-Heparin Triblock Copolymer Coating on Surfaces of Segmented Polyurethaneureas", in Artificial Heart 2, T. Akutsu, Ed., Springer-Verlag, Tokyo, pp. 45-53, (1988). 5. S. W. Kim, T. Okano, K.D. Park, D. W. Grainger and C. Nojiri, "Bioactive Polymer Surfaces: Improved Blood Compatibility", in Frontiers of Macromolecular Science, T. Saegusa, T. Higashimura, A. Abe, Eds., Blackwell Scientific Publications, 1989, pp. 561-566, (1989). 6. D. W. Grainger, T. Okano and S.W. Kim, "Protein Adsorption from Buffer and Plasma onto Hydrophilic-Hydrophobic Poly(ethylene oxide)-Polystyrene Multiblock Copolymers", J. Colloid Interface Sci. 132, 161-175 (1989). 7. D.W. Grainger, C. Nojiri, T. Okano, S.W. Kim, “In vitro and ex vivo platelet interactions with hydrophilic-hydrophobic poly(ethylene oxide)-polystyrene multiblock copolymers”, J. Biomed Mater. Res. Sep;23(9):979-1005. PubMed PMID: 2777836, (1989). 8. D. W. Grainger, A. Reichert, H. Ringsdorf and C. Salesse, "An Enzyme Caught in Action: Direct

Imaging of Hydrolytic Function and Domain Formation of Phospholipase A2 in Phosphatidylcholine Monolayers", FEBS Lett. 252, 73-82 (1989). 9. M. Ahlers, R. Blankenburg, D.W. Grainger, P. Meller, H. Ringsdorf and C. Salesse, "Specific Recognition and Formation of Two-Dimensional Streptavidin Domains in Monolayers: Applications to Molecular Devices", Thin Solid Films 180, 93-99 (1989). 10. C. Nojiri, K.D. Park, D.W. Grainger, H.A. Jacobs, T. Okano, H. Koyanagi, S.W. Kim, “In vivo nonthrombogenicity of heparin immobilized polymer surfaces”, ASAIO Trans. Jul-Sep;36(3):M168-72. PubMed PMID: 2252651, (1990) 11. D.W. Grainger, A. Reichert, H. Ringsdorf , C. Salesse, D.E. Davies, J.B. Lloyd, “Mixed monolayers of natural and polymeric phospholipids: structural characterization by physical and enzymatic methods”, Biochim. Biophys. Acta. Feb 28;1022(2):146-54. PubMed PMID: 2306452, (1990). 12. D.W. Grainger, K. Knutson, S.W. Kim, J. Feijen, “Poly(dimethylsiloxane)-poly(ethylene oxide)-heparin block copolymers. II: Surface characterization and in vitro assessments”, J. Biomed. Mater. Res. 1990 Apr;24(4):403-31. PubMed PMID: 2347871, (1990). 13. D.W. Grainger, T. Okano, S.W. Kim, D.G. Castner, B.D. Ratner, D. Briggs, Y.K. Sung, “Poly(dimethylsiloxane)-poly(ethylene oxide)-heparin block copolymers. III: Surface and bulk compositional differences”, J. Biomed. Mater. Res. May;24(5):547-71. PubMed PMID: 2324126, (1990). 14. D.W. Grainger, A. Reichert, H. Ringsdorf, C. Salesse “Hydrolytic action of phospholipase A2 in monolayers in the phase transition region: direct observation of enzyme domain formation using fluorescence microscopy”, Biochim. Biophys. Acta. Apr 30;1023(3):365-79. PubMed PMID: 2334729, (1990). 15. D.W. Grainger, M. Ahlers, R. Blankenburg, P. Meller, A. Reichert, H. Ringsdorf and C. Salesse, "Modeling of Cell Membrane Targeting: Specific Recognition, Binding, and Protein Domain Formation in Ligand-Containing Model Biomembranes", in Proc. NATO Adv.Stud. Symp.: Targeting of Drugs: Strategies and Optimizations, G. Gregoriadis, Ed., Plenum Press, New York, 1990, pp. 57-76, (1990). 16. D.W. Grainger, K. M. Maloney, X. Huang, M. Ahlers, A. Reichert, H. Ringsdorf, C. Salesse, J. N. Herron, V. Hlady, and K. Lim, "Binding, Interaction and Organization of Proteins with Lipid Model Membranes", in Progress in Membrane Biotechnology, J. C. Gomez-Fernandez, D. Chapman, L. Packer, Eds., Birkhauser Verlag, Zurich, pp. 64-82, (1991). 17. D.E. Davies, M. Critchlow, D.W. Grainger, A. Reichert, H. Ringsdorf, J.B. Lloyd, “Small unilamellar liposomes from mixed natural and polymeric phospholipids: stability and susceptibility to

phospholipase A2”. Biochim. Biophys. Acta, Jun 19;1084(1):29-34. PubMed PMID: 2054375, (1991). 18. D.W. Grainger, M. Ahlers, A. Reichert, H. Ringsdorf, C. Salesse, J.N. Herron and K. Lim, "Modeling Membrane Targeting: Interaction and Recognition of Proteins with Model Biomembrane Systems", (Invited paper at the Fifth Int. Symp. on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, 1991), J. Contr. Rel. 19, 201-218 (1992). 19. D.W. Grainger, M. Ahlers, P. Meller, R. Blankenburg, A. Reichert, H. Ringsdorf, C. Salesse, J. N. Herron and K. Lim, "Controlling Binding and Organization of Proteins with Model Biomembrane Systems Through Specific Recognition", (invited contribution), in Biomembrane Structure and Function: State of the Art, Adenine Press, pp. 53-80, (1992). 20. D.G. Castner, B.D. Ratner, D.W. Grainger, S.W. Kim, T. Okano, K. Suzuki, D. Briggs, S. Nakahama, “Surface characterization of 2-hydroxyethyl methacrylate/styrene copolymers by angle-dependent X-ray photoelectron spectroscopy and static secondary ion mass spectrometry”, J. Biomater. Sci. Polym. Ed.; 3(6):463-80. PubMed PMID: 1419975, (1992). 21. M. Ahlers, D.W. Grainger, J. N. Herron, K. Lim, H. Ringsdorf and C. Salesse, "Quenching of Fluorescein-Conjugated by Antibodies. Quantitative Recognition and Binding of Lipid-Bound Haptens in Biomembrane Models, Formation of Two-Dimensional Protein Domains and Molecular Dynamics Simulations" Biophys. J. 63, 823-838 (1992). 22. D.W. Grainger, J. Sunamoto, K. Akiyoshi, M. Goto and K. Knutson, "Mixed Monolayers and Cast Films of Acyl Ester and Acylamino Phospholipids", Langmuir 8, 2479-2485 (1992). 23. K.M Maloney, D.W. Grainger, “Phase separated anionic domains in ternary mixed lipid monolayers at the air-water interface”, Chem. Phys. Lipids. 1993 Apr;65(1):31-42. PubMed PMID: 8348675, (1993). 24. F. Sun and D.W. Grainger, "Ultrathin Self-Assembled Polymeric Films on Solid Surfaces. I. Synthesis and Characterization of Acrylate Copolymers Containing Alkyl Disulfide Side Chains", J. Polym. Sci. A, Polym. Chem. 31, 1729-1740 (1993). 25. H. Yu and D.W. Grainger, "Thermo-Sensitive Swelling Behavior in Crosslinked N-isopropylacrylamide Networks: Cationic, Anionic and Ampholytic Hydrogels", J. Appl. Polym. Sci. 49, 1553-1563 (1993). 26. F. Sun, D.G. Castner and D.W. Grainger, "Ultrathin Self-Assembled Polymeric Films on Solid Surfaces. 2. Formation of 11-(n-Pentyldithio)undecanoate-Bearing Polyacrylate Monolayers on Gold", Langmuir 9, 3200-3207 (1993). 27. K. Maloney and D.W. Grainger, "Biopolymer-Thin Film Interactions", MRS Symp. Proc. 292, 175-180 (1993). 28. Y.K. Sung, Y. J. Kim, D.W. Grainger, T. Okano and S. W. Kim, "Bulk and Thermal Characteristics of Poly(ethylene oxide)-Polystyrene Multiblock Copolymers", Korean Polym. J. 1, 14-20 (1993). 29. F. Sun, G. Mao, D. W. Grainger and D. G. Castner, "Polymer Ultrathin Films by Self Assembly: Bound Perfluorinated Monolayers and Their Modification Using In Situ Derivatization Strategies", Thin Solid Films 242, 106-111 (1994). 30. F. Sun, D. W. Grainger, D. G. Castner and D. K. Leach-Scampavia, "Adsorption of Ultrathin Films of Sulfur-Containing Siloxane Oligomers on Gold Surfaces and Their In Situ Modification", Macromolecules 27, 3053-3062 (1994). 31. F. Sun, D.W. Grainger and D.G. Castner, "Ultrathin Self-Assembled Polymeric Films on Solid Surfaces. III. Influence of Acrylate Dithioalkyl Side Chain Length on Polymeric Monolayer Formation on Gold", J. Vac. Sci. Technol. A, 12(4), 2499-2506 (1994). 32. H. Yu and D.W. Grainger, "Amphiphilic Thermosensitive N-isopropylacrylamide Terpolymer Hydrogels Prepared by Micellar Polymerization in Aqueous Media", Macromolecules 27, 4554-4560 (1994). 33. Y.J. Kim, Y. K. Sung, A.Z. Piao, D.W. Grainger, T. Okano and S.W. Kim, "Thermal and Structural Analysis of Heparin-PEO-PDMS-PEO-Heparin Pentablock Copolymers", J. Appl. Polym. Sci. 54, 1863-1872 (1994). 34. F. Sun, Y. Lei and D.W. Grainger, "Ultrathin Self-Assembled Polymer Films on Solid Surfaces. 4. Electrochemical Analysis of Film Microstructure on Gold Electrodes", Colloids Surf. A: Physicochem. Eng. Aspects 93, 191-200 (1994). 35. K.M. Maloney, M. Grandbois, D.W. Grainger, C. Salesse, K.A. Lewis, M.F. Roberts,

“Phospholipase A2 domain formation in hydrolyzed asymmetric phospholipid monolayers at the air/water interface”, Biochim. Biophys. Acta. 1995 May 4;1235(2):395-405. PubMed PMID: 7756350, (1995).

36. K.M. Maloney, M. Grandbois, D.W. Grainger, C. Salesse and A. Reichert, "Phospholipase A2 Interactions with Model Lipid Monolayer Membranes at the Air-Water Interface", ACS Symp. Ser., Proteins at Interfaces, (T. Horbett, J. Brash, ed.) ACS Press, Washington, DC, 490-504 (1995). 37. H. Yu and D.W. Grainger, "Modified Release of Hydrophilic, Hydrophobic and Peptide Agents from Ionized Amphiphilic Gel Networks", J. Controlled Rel. 34, 117-127 (1995). 38. W. Wang, D.G. Castner, D.W. Grainger, "Ultrathin Polysiloxane Films Bearing Grafted Perfluoroether Side Chains", in Chemically Modified Surfaces: Recent Developments, J. J. Pesek, M. T. Matyska and R. R. Abuelafiya, Eds. The Royal Society of Chemistry, Cambridge, 18-29, (1996). 39. F. Sun, D.G. Castner, G. Mao, W. Wang, P. McKeown, D.W. Grainger, "Spontaneous Polymer Thin Film Assembly and Organization Using Mutually Immiscible Side Chains", J. Am. Chem. Soc., 118, 1856-1866 (1996). 40. A.U. Schnurer, N.R. Holcomb, G.L. Gard, D.G. Castner and D.W. Grainger, "Photopolymerized Epoxide Copolymer Thin Films with Surfaces Highly Enriched with Sulfonyl Fluoride Groups", Chem. Mater. 8, 1475-1481 (1996). 41. Y.H. Liu, D.F. Evans, Q. Song and D.W. Grainger, "Structure and Frictional Properties of Self-Assembled Surfactant Monolayers", Langmuir 12, 1235-1241 (1996). 42. D.G. Castner, K. Hinds, D.W. Grainger, "X-ray Photoelectron Spectroscopy Sulfur 2p Study of Organic Thiol and Disulfide Interactions with Gold Surfaces", Langmuir 12, 5083-5086 (1996). 43. B.M. Discher, K.M. Maloney, W.R. Schief Jr., D.W. Grainger, V. Vogel , Hall SB, “Lateral phase separation in interfacial films of pulmonary surfactant”, Biophys J. (1996). Nov;71(5):2583-90. PubMed PMID: 8913596; PubMed Central PMCID: PMC1233745. 44. K.M. Maloney, M. Grandbois, C. Salesse, D.W. Grainger, A. Reichert, “Membrane microstructural templates for enzyme domain formation”, J. Mol. Recognit., 9(5-6):368-74. PubMed PMID: 9174912, (1996). 45. W. Wang, D.G. Castner and D.W. Grainger, "Ultrathin Films of Perfluoropolyether-Grafted Polysiloxanes Chemisorbed Via Alkylthiolate Anchors to Gold Surfaces", Supramolec. Sci. 4, 83-99, (1997). 46. G. Mao, D.G. Castner, D.W. Grainger, "Polymer Immobilization to Alkylchlorosilane Organic Monolayer Films Using Sequential Derivatization Reactions", Chem. Mater. 9, 1741-1750 (1997). 47. D.W. Grainger, "Synthetic Polymer Ultrathin Films for Modifying Surface Properties", Prog. Colloid Polym. Sci. 103, 243-250 (1997). 48. D.A. Jaeger, V.B. Reddy, N. Arulsamy, D.S. Bohle, D.W. Grainger, B. Berggren, "Hydrophobic Control of Diastereoselectivity in the Synthesis of Double-Chain Surfactant Co(III) Complexes", Langmuir 14, 2589-2592 (1998). 49. R. Winter, P.G. Nixon, G.L. Gard, D.G. Castner, N.R. Holcomb, Y-H. Hu, D.W. Grainger,

"Photopolymerized Acrylate Copolymer Films with Surfaces Enriched in Sulfur Pentafluoride (SF5) Chemistry", Chem. Mater. 11, 3044-3049 (1999). 50. A.G. Felts, G. Giridhar, D.W. Grainger, J.B. Slunt, “Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model”, Burns. 25(5):415-23. PubMed PMID: 10439150, (1999). 51. K.B. McClary, D.W. Grainger “, RhoA-induced changes in fibroblasts cultured on organic monolayers”. Biomaterials, Dec;20(23-24):2435-46. PubMed PMID: 10614948, (1999). 52. B.M. Discher, K.M. Maloney, D.W. Grainger, C.A. Sousa, S.B. Hall, “Neutral lipids induce critical behavior in interfacial monolayers of pulmonary surfactant”. Biochemistry, Jan 5;38(1):374-83. PubMed PMID: 9890919, (1999). 53. N.A. Barekzi, K.A. Poelstra, A.G. Felts, I.A. Rojas, J.B. Slunt, D.W. Grainger, “Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model”, Antimicrob. Agents Chemother. 43(7):1609-15. PubMed PMID: 10390211; PubMed Central PMCID: PMC89332, (1999). 54. S.R. Winn, J.M. Schmitt, D. Buck, Y. Hu, D.W. Grainger, J.O. Hollinger, "Tissue-engineered Bone Biomimetic to Regenerate Calvarial Critical-Sized Defects in Athymic Rats", J. Biomed. Mater. Res., 45, 414-421 (1999). PMID: 10321715 55. K.A. Poelstra, H.C. van der Mei, B. Gottenbos, D.W. Grainger, J.R. van Horn, H.J. Busscher, “Pooled human immunoglobulins reduce adhesion of Pseudomonas aeruginosa in a parallel plate flow chamber”, J. Biomed. Mater. Res. Aug;51(2):224-32. PubMed PMID: 10825222, (2000). 56. I.A. Rojas, J.B. Slunt, D.W. Grainger, “Polyurethane coatings release bioactive antibodies to reduce bacterial adhesion”, J. Control Release. Jan 3;63(1-2):175-89. PubMed PMID: 10640591, (2000). 56. K.A. Poelstra, N.A. Barekzi, D.W. Grainger, A.G. Gristina, T.C. Schuler, “A novel spinal implant infection model in rabbits”, Spine, Feb15;25(4):406-10. PubMed PMID: 10707383, (2000). 57. K.B. McClary, T. Ugarova, D.W. Grainger, “Modulating fibroblast adhesion, spreading, and proliferation using self-assembled monolayer films of alkylthiolates on gold”, J. Biomed. Mater. Res. Jun 5;50(3):428-39. PubMed PMID: 10737886, (2000). 58. K.A. Poelstra, N.A. Barekzi, J.B. Slunt, T.C. Schuler, D.W. Grainger, “Surgical irrigation with pooled human immunoglobulin G to reduce post-operative spinal implant infection”, Tissue Eng. Aug;6(4):401-11. PubMed PMID: 10992435, (2000). 59. A.G. Felts, D.W. Grainger, J.B. Slunt, “Locally delivered antibodies combined with systemic antibiotics confer synergistic protection against antibiotic-resistant burn wound infection”, J. Trauma. Nov;49(5):873-8. PubMed PMID: 11086779, (2000). 60. P.G. Nixon, R. Winter, D.G. Castner, N.R. Holcomb, D.W. Grainger, G.L. Gard, 6 "Pentafluoro-λ -sulfanyl (SF5)-Terminated Chlorosilanes: New SF5-Containing Films and Polysiloxane Materials", Chem. Mater. 12, 3108-3112 (2000).

61. R.W. Winter, P.G. Nixon, G.L. Gard, D.H. Radford, N.R. Holcomb, D.W. Grainger, "New SF5-Long Chain Carbon Systems", J. Fluorine Chem. 107, 23-30 (2000). 62. G.P. Beauregard, Y-H Hu, D.W. Grainger, S.P. James, "Silylation of Poly-L-Lysine Hydrobromide (PLL-HBr) to Improve Dissolution in Apolar Organic Solvents," J. Appl. Polym. Sci. 79, 2264-2271 (2001). 63. B.M. Discher, K.M. Maloney, D.W. Grainger, S.B. Hall, “Effect of neutral lipids on coexisting phases in monolayers of pulmonary surfactant”, Biophys Chem., Dec 10;101-102:333-45. PubMed PMID: 12488012, (2002). 64. Y. Hu, D.W. Grainger, S.R. Winn, J.O. Hollinger, “Fabrication of poly(alpha-hydroxy acid) foam scaffolds using multiple solvent systems”, J. Biomed. Mater. Res. Mar 5;59(3):563-72. PubMed PMID: 11774315, (2002). 65. K.A. Poelstra, N.A. Barekzi, A.M. Rediske, A.G. Felts, J.B. Slunt, D.W. Grainger, “Prophylactic treatment of gram-positive and gram-negative abdominal implant infections using locally delivered polyclonal antibodies”, J. Biomed. Mater. Res. Apr;60(1):206-15. PubMed PMID: 11835177, (2002). 66. N. Xia, Y-H Hu, D.W. Grainger, D.G. Castner, "Functionalized Poly(ethylene glycol)-Grafted Polysiloxane Monolayers for Control of Protein Binding", Langmuir 18, 3255-3262 (2002). 67. R.W. Winter, P.G. Nixon, R.J. Terjeson, J. Mohtasham, N.R. Holcomb, D.W. Grainger, D. Graham,

D.G. Castner, G.L. Gard, "Perfluorinated Polymer Surfaces Comprising SF5 Terminated Long-Chain Perfluoroacrylate", J. Fluorine Chem. 115(2), 107-113 (2002). 68. S.W. Metzger, M.J. Lochhead, D.W. Grainger, "Surface technologies to improve performance in protein microarray based molecular diagnostics", In Vitro Diagnostic Technol. 8(5), 39-45 (June 2002). 69. V. Tsukanova, D.W. Grainger and C. Salesse, "Monolayer Behavior of NBD-Labeled Phospholipids at the Air/Water Interface", Langmuir, 18: 5539-5550, (2002). 70. A.M. Rediske, A.L. Koenig, N. Barekzi, L.C. Ameen, J.B. Slunt, D.W. Grainger, “Polyclonal human antibodies reduce bacterial attachment to soft contact lens and corneal cell surfaces. Biomaterials. Dec;23(23):4565-72. PubMed PMID: 12322977, (2002). 71. N.A. Barekzi, A.G. Felts, K.A. Poelstra, J.B. Slunt, D.W. Grainger, “Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections”, Pharm. Res. Dec;19(12):1801-7. PubMed PMID: 12523657, (2002). 72. A.L. Koenig, V. Gambillara, D.W. Grainger, “Correlating fibronectin adsorption with endothelial cell adhesion and signaling on polymer substrates”, J. Biomed. Mater. Res. A. Jan 1;64(1):20-37. PubMed PMID: 12483693, (2003). 73. R.J. Christie, D.W. Grainger. “Design strategies to improve soluble macromolecular delivery constructs”, Adv. Drug Deliv. Rev. 24;55(3):421-37 (2003). PMID: 12628325. 74. D.W. Grainger, G. Pavon-Djavid, V. Migonney, M. Josefowicz, “Assessment of fibronectin conformation adsorbed to polytetrafluoroethylene surfaces from serum protein mixtures and correlation to support of cell attachment in culture”, J. Biomater. Sci. Polym. Ed. 14(9):973-88. PubMed PMID: 14661874, (2003). 75. D.W. Grainger, “Controlled-release and local delivery of therapeutic antibodies”, Expert Opin. Biol Ther. 4(7):1029-44 (2004) PMID: 15268671. 76. R. Winter, P.G. Nixon, G.L. Gard, D.J. Graham, D.G. Castner, N.R. Holcomb, D.W. Grainger, “Self-assembled organic monolayers terminated in perfluoroalkyl pentafluoro-lambda(6)-sulfanyl (-SF5) chemistry on gold”, Langmuir. 6;20(14):5776-81. PMID: 16459592, (2004). 77. P. Wu, D.W. Grainger, “Toward immobilized antibody microarray optimization: print buffer and storage condition comparisons on performance”, Biomed. Sci. Instrum. 40:243-8 (2004); PMID: 15133965. 78. P. Gong and D.W. Grainger, “Comparison of DNA Immobilization Efficiency on New and Regenerated Commercial Amine-reactive Polymer Microarray Surfaces,” Surf. Sci. 570(1-2) 67-77 (2004). 79. M.L. Godek, N.L. Duchsherer, Q. McElwee, D.W. Grainger, “Morphology and growth of murine cell lines on model biomaterials”. Biomed. Sci. Instrum., 2004;40:7-12 (2004) PMID: 15133927. 80. R.J. Christie, D.J. Findley, D.W. Grainger, “Design and synthesis of a new polymer drug delivery conjugate”, Biomed. Sci. Instrum. 40:136-41 (2004) PMID:15133948. 81. P. Gong, D.W. Grainger, “Analysis of regenerated amine-reactive polymer microarray slides”, Biomed. Sci. Instrum., 40:18-23 (2004) PMID: 15133929. 82. L. Wally, N.E. Levinger, D.W. Grainger, “Employing Popular Children’s Literature to Teach Elementary School Chemistry: An Engaging Outreach Program,” J. Chem. Educ. 82(10) 1489-1495 (2005). 83. M.L. Godek, J.A. Sampson, N.L. Duchsherer, Q. McElwee, D.W. Grainger, “Rho GTPase protein expression and activation in murine monocyte/macrophages is not modulated by model biomaterial culture surfaces,” J. Biomat. Sci. Polym. Ed., 17(10), 1141-1158 (2006). doi: 10.1163/156856206778530731; PMCID: PMC1776857; NIHMSID: NIHMS14057 84. P. Wu, P. Hogrebe, D.W. Grainger, “DNA and protein microarray printing on silicon nitride waveguide surfaces”, Biosens. Bioelectron. Jan 15;21(7):1252-63. Epub 2005 Jul 5. PubMed PMID: 16002276, (2006). 85. P. Wu, D.W. Grainger, “Drug/device combinations for local drug therapies and infection prophylaxis”. Biomaterials, (2006) 27(11):2450-67; PubMed PMID: 16337266, (2006). 86. R.J. Christie, D.J. Findley, M. Dunfee, R.D. Hansen, S.C. Olsen, D.W. Grainger, “Photopolymerized hydrogel carriers for live vaccine ballistic delivery”, Vaccine, Feb 27;24(9):1462-9. Epub 2005 Oct 3. PubMed PMID: 16246467, (2006). 87. S.C. Olsen, R.J. Christie, D.W. Grainger, W.S. Stoffregen, “Immunologic responses of bison to vaccination with Brucella abortus strain RB51: comparison of parenteral to ballistic delivery via compressed pellets or photopolymerized hydrogels”, Vaccine. Feb 27;24(9):1346-53. Epub 2005 Sep 29. PubMed PMID: 16236400, (2006). 88. P. Gong, G.M. Harbers, D.W. Grainger, “Multi-technique comparison of immobilized and hybridized oligonucleotide surface density on commercial amine-reactive microarray slides”, Anal. Chem. Apr 1;78(7):2342-51. PubMed PMID: 16579618, (2006). 89. P. Gong, C.Y. Lee, L.J. Gamble, D.G. Castner, D.W. Grainger, “Hybridization behavior of mixed DNA/alkylthiol monolayers on gold: characterization by surface plasmon resonance and 32P radiometric assay”, Anal. Chem. 2006 May 15;78(10):3326-34. PubMed PMID: 16689533; PubMed Central PMCID: PMC1866305, (2006). 90. C.Y. Lee, P. Gong, G.M. Harbers, D.W. Grainger, D.G. Castner, L.J. Gamble, “Surface coverage and structure of mixed DNA/alkylthiol monolayers on gold: characterization by XPS, NEXAFS, and fluorescence intensity measurements”, Anal. Chem. 2006 May 15;78(10):3316-25. PubMed PMID: 16689532, (2006). 91. M.L. Godek, G.S. Malkov, E.R. Fisher, D.W. Grainger, “Macrophage Serum-Based Adhesion to Plasma-Processed Surface Chemistry is Distinct from That Exhibited by Fibroblasts”. Plasma Process Polym. Aug 15;3(6-7):485-497. PubMed PMID: 17417668; PubMed Central PMCID: PMC1847953, (2006). 92. C-Y Lee, L.J. Gamble, D.W. Grainger, D.G. Castner, “Mixed DNA/Oligoethylene glycol functionalized gold surfaces improve DNA hybridization in complex media”, BioInterphases, 1, 83-92 (2006). 93. P. Wu, D.W. Grainger, “Comparison of hydroxylated print additives on antibody microarray performance” J. Proteome Res., Nov;5(11):2956-65. PubMed PMID: 17081047; PubMed Central PMCID: PMC2528199, (2006). 94. D.S. Dandy, P. Wu, D.W. Grainger, “Array feature size influences nucleic acid surface capture in DNA microarrays”, Proc. Natl. Acad. Sci. USA. May 15;104(20):8223-8. Epub 2007 May 7. PubMed PMID: 17485675; PubMed Central PMCID: PMC1895933, (2007). 95. D. Xue, C.M. Elliott, P. Gong, D.W. Grainger, C.A. Bignozzi, S. Caramori, “Indirect electrochemical sensing of DNA hybridization based on the catalytic oxidation of cobalt (II)”, J. Am. Chem. Soc. Feb 21;129(7):1854-5. Epub 2007 Jan 30. PubMed PMID: 17260990; PubMed Central PMCID: PMC2546519, (2007). 96. C.Y. Lee, P.C. Nguyen, D.W. Grainger, L.J. Gamble, D.G. Castner, “Structure and DNA hybridization properties of mixed nucleic acid/maleimide-ethylene glycol monolayers” Anal. Chem. Jun 15;79(12):4390-400. Epub 2007 May 11. PubMed PMID: 17492838; PubMed Central PMCID: PMC2518630, (2007). 97. I.C. Saldarriaga Fernández, H.C. van der Mei, M.J. Lochhead, D.W. Grainger, H.J. Busscher, ”The inhibition of the adhesion of clinically isolated bacterial strains on multi-component cross-linked poly(ethylene glycol)-based polymer coatings”, Biomaterials. Oct;28(28):4105-12. Epub 2007 Jun 15. PubMed PMID: 17573108, (2007). 98. R. Kuijer, E.J. Jansen, P.J. Emans, S.K. Bulstra, J. Riesle, J. Pieper, D.W. Grainger, H.J. Busscher, ”Assessing infection risk in implanted tissue-engineered devices”, Biomaterials. Dec;28(34):5148-54. Epub 2007 Jun 26. PubMed PMID: 17597202, (2007). 99. J.A. Auer, A. Goodship, S. Arnoczky, S. Pearce, J. Price, L. Claes, B. von Rechenberg, M. Hofmann-Amtenbrinck, E. Schneider, R. Müller-Terpitz, F. Thiele, K.P. Rippe, D.W. Grainger, “Refining animal models in fracture research: seeking consensus in optimising both animal welfare and scientific validity for appropriate biomedical use”, BMC Musculoskelet. Disord. (2007) 8:72. PubMed PMID: 17678534; PubMed Central PMCID: PMC1952063. 100. C.Y. Lee, G.M. Harbers, D.W. Grainger, L.J. Gamble, D.G. Castner. “Fluorescence, XPS, and TOF-SIMS surface chemical state image analysis of DNA microarrays” J. Am. Chem. Soc. Aug 1;129(30):9429-38. Epub 2007 Jul 11. PubMed PMID: 17625851; PubMed Central PMCID: PMC2533279, (2007). 101. G.M. Harbers, K. Emoto, C. Greef, S.W. Metzger, H.N. Woodward, J.J. Mascali, D.W. Grainger, M.J. Lochhead, “A functionalized poly(ethylene glycol)-based bioassay surface chemistry that facilitates bio-immobilization and inhibits non-specific protein, bacterial, and mammalian cell adhesion”, Chem Mater. 2007;19(18):4405-4414. PubMed PMID: 18815622; PubMed Central PMCID: PMC2546567, doi 10.1021/cm070509u, (2007). 102. D.W. Grainger, “Peer review as professional responsibility: a quality control system only as good as the participants” Biomaterials. Dec;28(34):5199-203. Epub 2007 Jul 23. PubMed PMID: 17643484, (2007). 103. F. Cheng, L.J. Gamble, D.W. Grainger, D.G. Castner, “X-ray photoelectron spectroscopy, time-of-flight secondary ion mass spectrometry, and principal component analysis of the hydrolysis, regeneration, and reactivity of N-hydroxysuccinimide-containing organic thin films”, Anal. Chem. (2007) 79(22):8781-8. PMID: 17929879; PMCID: PMC2536634. 104. C.M. Santoro, N.L. Duchsherer, D.W. Grainger, “Antimicrobial efficacy and ocular cell toxicity from silver nanoparticles”, Nanobiotechnology. (2007) 3(2):55-65. PubMed PMID: 19865601; PMCID: PMC2768321, (2007). 105. H. Takahashi, D. Letourneur, D.W. Grainger, “Delivery of large biopharmaceuticals from cardiovascular stents: a review”, Biomacromolecules. Nov;8(11):3281-93. Epub 2007 Oct 12. PubMed PMID: 17929968; PubMed Central PMCID: PMC2606669, (2007). 106. D.W. Grainger, D.G. Castner, “Nanobiomaterials and nanoanalysis: how to improve the nanoscience for biotechnology”, Adv. Mater. 20, 867–877 (2008). 107. P. Wu, D.G. Castner, D.W. Grainger, “Diagnostic devices as biomaterials: a review of nucleic acid and protein microarray surface performance issues”, J. Biomater. Sci. Polym. Ed. 19(6):725-53. Review. PubMed PMID: 18534094, (2008). 108. M.L. Godek, R. Michel, L.M. Chamberlain, D.G. Castner, D.W. Grainger, “Adsorbed serum albumin is permissive to macrophage attachment to perfluorocarbon polymer surfaces in culture”, J. Biomed. Mater. Res. A. 2009 Feb;88(2):503-19. PubMed PMID: 18306309.doi 10.1002/jbm.a.31886 (2008). 109. H. Takahashi, M. Dubey, K. Emoto, D.G. Castner, D.W. Grainger, “Imaging surface immobilization chemistry: correlation with cell patterning on non-adhesive hydrogel thin films”, Adv. Funct. Mater., (2008) 18 2079-2088. doi: 10.1002/adfm.200800105; PMCID: PMC2917816 NIHMSID: NIHMS187260. 110. N. Ayres, D.J. Holt, C.F. Jones, L.E. Corum, D.W. Grainger, “Polymer Brushes Containing Sulfonated Sugar Repeat Units: Synthesis, Characterization and In Vitro Testing of Blood Coagulation Activation”, J. Polym. Sci. A. Polym. Chem.;46(23):7713-7724. PubMed PMID: 19859552; PubMed Central PMCID: PMC2766538. doi 10.1002/pola.230752008, (2008). 111. R. J. Christie, C. Tadiello, D.W. Grainger, “Preparation and Optical Properties of a Novel Thiol-Derivatized Tetramethylrhodamine Dye”, Bioconj. Chem. doi: 10.1021/bc800367e, 20(3), 476-480 (2009); PMCID: PMC2676207 112. C.F. Jones, D.W. Grainger, “In vitro assessments of nanomaterial toxicity”, Adv. Drug Deliv. Rev. 2009; 61(6):438-56. PMID 19383522; PMC2763955. doi:10.1016/j.addr.2009.03.005, 61 438-456. 113. D.W. Grainger, “Nanotoxicity assessment: all small talk?”, Adv. Drug Deliv. Rev. 2009 Jun 21;61(6):419-21. Epub 2009 Apr 19. doi:10.1016/j.addr.2009.04.003, (2009). 114. M. Dubey, K. Emoto, F. Cheng, L.J. Gamble, H. Takahashi, D.W. Grainger, D.G. Castner. “Surface Analysis of Photolithographic Patterns using ToF-SIMS and PCA”, Surf Interface Anal. 2009 Mar 18;41(8):645-652. PMC2743017, doi 10.1002/sia.3056, (2009). 115. D.M. Higgins, R.J. Basaraba, A.C. Hohnbaum, E.J. Lee, D.W. Grainger, M. Gonzalez-Juarrero, “Localized immunosuppressive environment in the foreign body response to implanted biomaterials” Am. J. Pathol. Jul;175(1):161-70. (2009) PMC2708803. 116. M. Dubey, K. Emoto, H. Takahashi, D.G. Castner, D. W. Grainger, “Affinity-based Protein “Surface Pattern Formation by Ligand Self-Selection from Mixed Protein Solutions”, Adv. Funct. Mater. 19, 3046–3055; doi10.1002/adfm.200900809, (2009). 117. L.M. Chamberlain, M.L. Godek, M. Gonzalez-Juarrero, D. W. Grainger, “Phenotypic non-equivalence of murine (monocyte-) macrophage cells in biomaterial and inflammatory models”, J. Biomed. Mater. Res. A. Mar 15;88(4):858-71. PMID: 18357567, (2009). 118. D.W. Grainger, “Engaging in quality technical peer review as an international professional responsibility; those who publish confidently must also review competently”, Revista Ingeniria Biomedica, 3(5) 66-73 (2009). (both English and Spanish full translation) 119. D.W. Grainger, “DNA nanotechnology: geometric sorting boards,” News and Views, Nature Nanotechnology, doi:10.1038/nnano.2009.249, 4:543-544. PMID: 19734919, (2009). 120. I.C. Saldarriaga Fernández, H.C. Mei, S. Metzger, D.W. Grainger, A.F. Engelsman, M.R. Nejadnik, H.J. Busscher, “In vitro and in vivo comparisons of staphylococcal biofilm formation on a cross linked poly(ethylene glycol)-based polymer coating” Acta. Biomater. 6(3):1119-24. PMID: 19733265, (doi:10.1016/j.actbio.2009.08.040) (2010). 121. F. Liu, M. Dubey, H. Takahashi, D.G. Castner, D.W. Grainger, “Immobilized Antibody Orientation Analysis using Secondary Ion Mass Spectrometry and Fluorescence Imaging of Affinity-generated Patterns”, Analytical Chem., 82, 2947–2958 (2010); DOI 10.1021/ac902964q. PMID 20230047 122. Y. Wang, D.W. Grainger, “siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption”, Pharm. Res., 27(7) 1273-1279, (2010). doi 10.1007/s11095-010-0099-5 (2010). PMC2885461. PMC2885461. PMID: 20333451 + + + 123. M. Dubey, J. Brison, D.W. Grainger, D.G. Castner, “Comparison of Bi1 , Bi3 and C60 primary ion sources for ToF-SIMS imaging of patterned protein samples”, Surf. Interface Anal., 2011, 43, 261–264; doi 10.1002/sia.3537, NIHMS211440. PMID: 21516225. 124. H. Takahashi, Y. Wang, D.W. Grainger, “Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation”, J. Control Rel., 147 (2010) 400–407 doi:10.1016/j.jconrel.2010.08.019. PMC2975752. PMID: 20727922. 125. R.J. Christie, D. Anderson, D.W. Grainger, "Comparison of Hydrazone Heterobifunctional Crosslinking Agents for Reversible Conjugation of Thiol-Containing Chemistry", Bioconj. Chem., e-pub on-line, (2010). doi 10.1021/bc100049c; PMC2676207. PMID: 20695431 126. D. Holt, L. Chamberlain, D.W. Grainger, “Cell-cell signaling in co-cultures of macrophages and fibroblasts,” Biomaterials, 31 (2010) 9382-9394. doi:10.1016/j.biomaterials.2010.07.101. PMC2976809. PMID: 20932568 127. Sevy JO, Slawson MH, Grainger DW, Brooks AE. “Assay Method for Polymer-Controlled Antibiotic Release from Allograft Bone to Target Orthopaedic Infections” Biomed Sci Instrum., 46, (2010) 136-41. PMID: 20467084 128. Davidoff SN, Call BP, Hogrebe PH, Grainger DW, Brooks AE.” A Robust Method to Coat Allograft Bone with a Drug-Releasing Polymer Shell” Biomed. Sci. Instrum., 46, (2010) 184-189. PMID: 20467092 129. I.C. Saldarriaga Fernández, H. J. Busscher, S. Metzger, D.W. Grainger, H.C. van der Mei, “Simultaneous interaction of staphylococci and osteoblasts in co-culture crosslinked poly(ethylene glycol)-based polymer coatings” Biomaterials, 32 (2011) 979-984; doi 10.1016/j.biomaterials.2010.10.011 PMID: 20980049 130. Y. Wang, A. Panasiuk, D.W. Grainger, “Small interfering RNA knock-down of farnesyl pyrophosphate synthase to control osteoclasts,” Molec. Pharm., 8(4):1016-1024 (2011) NIHMSID 264933; PMID: 21186792; PMC3084905. 131. D. Holt, L. Chamberlain, D.W. Grainger, “Multi-nucleated fibroblasts in co-cultures”, Biomaterials, 32 (2011) 3977-3987. PMC3071287. PMC3071287. PMID: 21397323 132. I.C. Saldarriaga Fernández, J.F. Da Silva Domingues, T.G. van Kooten, S. Metzger, D.W. Grainger, H.J. Busscher, H.C. van der Mei, “Macrophage response to staphylococcal biofilm on crosslinked poly(ethylene) glycol polymer coatings in vitro”, Eur. Cells Mater, 21 (2011) 73-79. PMID: 21240846 133. Davidoff SN, Sevy JO, Brooks BD, Grainger DW, Brooks AE. “Evaluating Antibiotic Release Profiles As A Function Of Polymer Coating Formulation” Biomed. Sci. Instrum., 47, 46-51 (2011). PMID: 21525595 134. D. Diekjürgen, A. Astashkina, D.W. Grainger, D. Holt, A.E. Brooks, “Cultured Primary Macrophage Activation by Lipopolysaccharide Depends on Adsorbed Protein Composition and Substrate Surface Chemistry“, J. Biomater. Sci. Polym. Ed., 23(9) 1231-1254 (2012). DOI:10.1163/092050611X580382; PMID: 21722418. 135. Y. Wang, D.W. Grainger, “RNA therapeutics targeting osteoclast-mediated excessive bone resorption”, Adv. Drug Del. Rev., 64 (2012) 1341–1357. (doi:10.1016/j.addr.2011.09.002). PMID: 21945356 136. W. Sanders, P. Hogrebe, D.W. Grainger, A. K. Cheung, C. M. Terry “A biodegradable perivascular wrap for controlled, local and directed drug delivery”, J. Control. Rel., 161 (2012) 81–89. PMID: 22561340; PMC3378780. 137. A. Astashkina, B. Mann, D.W. Grainger, “A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity.,” Pharmacol Ther., 134 82-106 (2012); doi 10.1016/j.pharmthera.2012.01.001; PMID: 22252140 138. A. Astashkina, B. Mann, G. Prestwich, D.W. Grainger, “A 3-D Organoid Kidney Culture Model Engineered for High Throughput Nephrotoxicity Assays”, Biomaterials 33 (2012) 4700-4711; doi 10.1016/j.biomaterials.2012.02.063 PMID: 22444643 139. A. Astashkina, B. Mann, G. Prestwich, D.W. Grainger, “Comparing predictive drug nephrotoxicity biomarkers in kidney 3-D primary organoid culture and immortalized cell lines”, Biomaterials 33 (2012) 4712-4721; doi 10.1016/j.biomaterials.2012.03.001. PMID: 22475530 140. C.F Jones, R.A Campbell, Z. Franks, C.C. Gibson, G. Thiagarajan, A. Vieira-de-Abreu, S. Sukavaneshvar, S.F. Mohammad, D.Y. Li, H. Ghandehari, A.S. Weyrich, B.D. Brooks, DW. Grainger, “Cationic PAMAM dendrimers disrupt key platelet functions”, Molec. Pharm., 9(6):1599-611 (2012). PMID: 22497592. 141. D. Holt, D.W. Grainger, “Demineralized bone matrix as a vehicle for delivering endogenous and exogenous therapeutics in bone repair”, Adv. Drug Deliv. Rev., 64 (2012) 1123–1128. doi10.1016/j.addr.2012.04.002, 2012. PMID: 22521662 142. D. Holt, D.W. Grainger, “Senescence and quiescence in cultured macrophages", Biomaterials 33 (2012) 7497-7507. PMID: 22809642 143. D.W. Grainger, “Targeted delivery of therapeutics to bone and connective tissues”, Adv. Drug Del. Rev. 64 (2012) 1061–1062. PMID: 22967673 144. R.G. Richards. T. Miclau, T.F. Moriarty, R.T. McClellan, D.W. Grainger, “Advances in biomaterials and surface technologies,” J. Orthoped. Trauma, e-pub, August, 2012, PMID 22913967, 2012. 145. Y. Wang, K.K. Tran, H. Shen, D.W. Grainger, Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials, Biomaterials, 2012 Nov;33(33):8540-7. doi: 10.1016/j.biomaterials.2012.07.039. PMID: 22951320 146. H. J. Busscher, H. C. van der Mei, G. Subbiahdoss, P. C. Jutte, J. J. A. M. van den Dungen, S. A. J. Zaat, M. J. Schultz, D.W. Grainger, Biomaterial-associated infection: Locating the finish line in the race for the surface. Sci. Transl. Med. 4, 153rv10 (2012). PMID: 23019658 147. A.N. Rao, C. Rodesch, D.W. Grainger, “Real-time fluorescent image analysis of DNA spot hybridization kinetics to assess microarray spot heterogeneity" Analytical Chem., 84(21) 9379-9387. DOI: 10.1021/ac302165h, 2012. PMID: 23043216. 148. C.F. Jones, R.A. Campbell, S. Assemi, G. Thiagarajan, H. Ghandehari, A.E. Brooks, A.S. Weyrich, B.D. Brooks, D.W. Grainger, “Cationic PAMAM dendrimers aggressively initiate blood clot formation,” ACS Nano, 2012 6(11):9900-10; DOI: 10.1021/nn303472r. PMID: 23062017 149. A.N. Rao, N. Vandencasteele, L. Gamble, D.W. Grainger, “High resolution epifluorescence and TOF-SIMS chemical imaging comparisons of single DNA microarray spots,” Analytical Chemistry, 84(24):10628-36, 2012; PMID: 23150996; DOI: 10.1021/ac3019334 150. H. Takahashi, D.G. Castner, D.W. Grainger, Surface analysis of protein patterns fabricated by affinity-based surface ligand selection from protein solution mixtures, Chapter 36 in ACS Symp. Ser. “Proteins at Interfaces III”, (T. Horbett, W. Norde, J. Brash, eds.), ACS Press, Washington, DC, 2012, pp, 781-807. 151. D.W. Grainger, “Connecting drug delivery reality to smart materials design,” Int. J. Pharm, 454 (2013) 521-524; doi:10.1016/j.ijpharm.2013.04.061. 152. K.J. Smock, R.L. Schmidt, G. Hadlock, G. Stoddard, D.W. Grainger, M.A. Munger, “Assessment of Orally Dosed Commercial Silver Nanoparticles on Human ex vivo Platelet Aggregation,” Nanotoxicol., 2014 8(3):328-33 (PMID: 23517080). DOI: 10.3109/17435390.2013.788749 153. M.A. Munger, P. Radwanski, G. Hadlock, G. Stoddard, A. Shaaban, J. Falconer, D.W. Grainger, G. Yost, “In vivo human time-exposure study of orally dosed commercial silver nanoparticles,” Nanomedicine: NBM, 2014, 10(1):1-9, http://dx.doi.org/10.1016/j.nano.2013.06.010. PMC3877176; NIHMSID: NIHMS501656. 154. D.W. Grainger, “All charged up about biomaterials,” (News and Views), Nature Biotechnol., 31, 507–509 (2013) doi:10.1038/nbt.2600. 155. A.E. Brooks, B.D. Brooks, S.N. Davidoff, P.C. Hogrebe, M.A. Fisher, and D.W. Grainger, “Polymer-controlled release of tobramycin from bone graft void filler,” Drug Deliv. Transl. Res., (2013) 3(6):518–530; DOI 10.1007/s13346-013-0155-x 156. D.W. Grainger, H.C. van der Mei, P.C. Jutte, J.J.A.M. van den Dungen, M.J. Schultz, B.F.A.M. van der Laan, S.A.J. Zaat, H.J. Busscher, “Critical factors in the translation of improved antimicrobial strategies for medical implants and devices”, Biomaterials, 2013 Dec;34(37):9237-43. doi: 10.1016/j.biomaterials.2013.08.043. Epub 2013 Sep 11, PMID: 24034505. 157. Y. Wang, D.W. Grainger, “Developing siRNA therapies to address osteoporosis“, Therap. Deliv., 4(10):1239-46 (2013). doi: 10.4155/tde.13.85. 158. M.N. Avula, A. Rao, L.D. McGill, F. Solzbacher, D.W. Grainger, “Modulation of the foreign body response to implanted sensor models through device-based delivery of the tyrosine kinase inhibitor, masitinib, Biomaterials 34 9737-9746 (2013), http://dx.doi.org/10.1016/j.biomaterials.2013.08.090; PMID: 24060424. 159. A. Rao, C. Rodesch, D.W. Grainger, “Correction to the Supporting information of Real-time fluorescent image analysis of DNA spot hybridization kinetics to assess microarray spot heterogeneity,” Anal. Chem. 85(8) 4199 (2013). PMID 23551146. 160. S.N. Davidoff, S.T. Lawson, D.W Grainger, A.E Brooks, Scanning electron image analysis to monitor of implant degradation and host healing following implantation of a drug-eluting bone graft void filler, Biomed Sci Instrum. 2013;49:165-71. PMID: 23686196. 161. B.D. Brooks, K.D. Sinclair, S.N. Davidoff, S. Lawson, A.G. Williams, B. Coates, D.W. Grainger, A.E. Brooks, “Molded Polymer-Coated Composite Bone Void Filler Improves Tobramycin Controlled Release Kinetics", J. Biomed. Mat. Res. B (Appl. Biomaterials), 2014 102(B):1074-83. doi: 10.1002/jbm.b.33089, PMID: 24376164. 162. F.J. Silva, D.J. Holt, V. Vargas, J. Yockman, S. Boudina, D. Atkinson, D.W. Grainger, M.P. Revelo, W. Sherman, D.A. Bull, A.N. Patel, “Metabolically active human brown adipose tissue derived stem cells”, Stem Cells, 32: 572–581 (2014); doi: 10.1002/stem.1595. 163. M. Avula, A. Rao, F. Solzbacher, D.W. Grainger, “Foreign Body Response to Subcutaneous Biomaterial Implants in a Mast Cell-deficient Kitw-Sh Murine Model,” Acta Biomaterialia, 10(5):1856-63 (2014). doi: 10.1016/j.actbio.2013.12.056; PMID: 24406200. 164. S. Davidoff, B. Brooks, D.W. Grainger, A.E. Brooks, “Comparisons of release of several antibiotics from antimicrobial polymer-coated allograft bone void filler,” Intl J. Biomed. Mat. Res., (2013) 1(2): 21-25; doi: 10.11648/j.ijbmr.20130102.11. 165. Romanov V, Davidoff SN, Miles AR, Grainger DW, Gale BK, Brooks BD. “A Critical Comparison of Protein Microarray Fabrication Technologies”, Analyst, (2014) Feb 17;139(6):1303-26. doi: 10.1039/c3an01577g. 166. DeGooyer J, Davidoff SN, Brooks BD, Grainger DW, Brooks AE., “Polymer-controlled extended combination release of silver and chlorhexidine from a bone void filler,” Biomed Sci Instrum. 2014;50:47-53. PMID: 25405403 167. A. Rao, D.W. Grainger, “Biophysical aspects of nucleic acids on surfaces relevant to microarray performance, Biomaterials. Sci., (2014) 2(4), 436-471. DOI:10.1039/C3BM60181A. 168. Y. Wang, J. Liu, J. Zhang, L. Wang, J. Chan, H. Wang, Y. Jin, L. Yu, D.W. Grainger, W. Ying, “A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs,” Intl J. Med Sci., 2014; 11(5): 479-487. doi: 10.7150/ijms.8340 169. A. Astashkina, D.W. Grainger, “Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments,” Adv. Drug Del. Rev., 69-70:1-18. (2014) doi: 10.1016/j.addr.2014.02.008. 170. D.W. Grainger, “Cell-based drug testing; this world is not flat”, Adv. Drug Del. Rev, 69:vii-xi (2014) 10.1016/j.addr.2014.04.001. 171. A. Astashkina, C. Jones, K. Kurtzeborn, G. Thiagurajan, H. Ghandehari, B. Brooks, D.W. Grainger, “A 3-D organoid in vitro kidney model for in vivo nanomaterials toxicity assessment,” Biomaterials, 2014 35(24):6323-31. doi: 10.1016/j.biomaterials.2014.04.060. PMID 24814424. 172. T.F. Moriarty, D.W. Grainger, R.G. Richards, Challenges in linking preclinical anti-microbial research strategies with clinical outcomes for device-associated infections, Eur Cells Mater. 28 112-128 (2014). PMID: 25214018. 173. Y. Wang, D.W. Grainger, “Barriers to Advancing Nanotechnology to Better Improve and Translate Nanomedicines" Front. Chem. Sci. Eng., (2014) 8(3): 265-275; DOI: 10.1007/s11705-014-1442-x. 174. G.N. Duda, D.W. Grainger, M.L. Frisk, L. Bruckner-Tuderman, A. Carr, U. Dirnagl, K.M. Einhäupl, S. Gottschalk, E. Gruskin, C. Huber, C.H. June, D.J. Mooney, E. Th. Rietschel, G. Schütte, W. Seeger, M.M. Stevens, R. Urban, A. Veldman, G. Wess, H-D. Volk, “Changing the Mindset in Life Sciences toward Translation: A Consensus,” Sci. Trans. Med. 6, 264cm12 (2014). 175. B.D. Brooks, K.D. Sinclair, D.W. Grainger, A.E. Brooks, “A Resorbable Antibiotic-Eluting Polymer Composite Bone Void Filler for Perioperative Infection Prevention in a Rabbit Radial Defect Model,” PLoS One, 2015 Mar 27;10(3):e0118696. doi: 10.1371/journal.pone.0118696D. 176. Chamberlain LM, Holt-Casper D, Gonzalez-Juarrero M, Grainger, DW. 2015. Extended culture of macrophages from different sources and maturation results in a common M2 phenotype. J Biomed Mater Res Part A, 2015:103A:2864–2874; doi:10.1002/jbm.a.35415; PMC4520783 177. H.-D. Volk, M.M. Stevens, D.J. Mooney, D.W. Grainger,, G.N. Duda, Key elements for nourishing the translational research environment. Sci. Transl. Med. 7, 282cm2 (2015). 178. D.W. Grainger, “Wound healing: enzymatically crosslinked scaffolds,” Nature Materials 14, 662–663 (2015) doi:10.1038/nmat4337, 2015. (PMID 26099714) 179. M. Hofmann-Amtenbrink, D.W. Grainger, H. Hofmann, “Nanoparticles in Medicine: Current Challenges Facing Inorganic Nanoparticle Toxicity Assessments and Standardizations,” Nanomedicine, 2015, 11(7) 1689–1694; DOI: http://dx.doi.org/10.1016/j.nano.2015.05.005 180. D.W. Grainger, “Fat prospects for healing cutaneous wounds: new activities under the sheets,” Diabetes (commentary), 64: 2717-2719, 2015. 181. J. Auer, D.W. Grainger, “Fracture management in horses: Where have we been and where are we going?”, Vet. J., ePub June 20, 2015; doi: 10.1016/j.tvjl.2015.06.002. (PMID 26095036) 182. J. Falconer, S. Lu, C. Jones, D.W Grainger, “Carbon Nanomaterials Rescue Polyaromatic Hydrocarbon Toxicity in Zebrafish Embryo Cultures”, Environ. Sci. Nano, 2015, 2, 645 – 652; DOI: 10.1039/C5EN00111K. 183. D.J. Holt, A. Moreno, M. Warren, J.M. Theisen, D.W. Grainger, D.A. Bull, A.N. Patel, Highly cellularized three-dimensional human heart matrix-derived scaffolds, J. Trans. Med., 13:194, 2015. (PMID 26084398). 184. H. Herd Gustafson, D. Holt-Casper, D.W. Grainger, H. Ghandehari,, “Nanoparticle Uptake: The Phagocyte Problem“, NanoToday, 2015 Aug; 10(4): 487-510. doi: 10.1016/j.nantod.2015.06.006; PMCID: PMC4666556; NIHMSID: NIHMS707252. 185. K.D. Sinclair, Z.A. Farrell, B.D. Brooks, A.E. Brooks, D.W. Grainger, “A Resorbable Antibiotic-Eluting Polymer Composite Bone Void Filler for Periprosthetic Joint Infection Prevention”, J. Biomed. Mater. Res. B., ePub 2015; doi: 10.1002/jbm.b.33513. PMID: 26332762. 186. M. Avula, D. Jones; A. Rao, D. McClain, L.D. McGill, D.W. Grainger; F. Solzbacher, “Local release of masitinib alters in vivo implantable continuous glucose sensor performance”, Biosensors Bioelectron. (2016) 77 149–156;10.1016/j.bios.2015.08.059, 2015. 187. J. L. Falconer, R.J. Christie, E.J. Pollard, S.C. Olsen, D.W. Grainger, “Live RB51 Vaccine Lyophilized Hydrogel Formulations with Increased Shelf Life for Practical Ballistic Delivery,” Int. J. Pharm, 498 (2016) 187–194. 188. J. Aamodt, D.W. Grainger, Extracellular Matrix-based Biomaterial Scaffolds and the Host Response, Biomaterials, (2016) 86 68–82. doi:10.1016/j.biomaterials.2016.02.003. 189. Winters AA, Bou-Ghannam S, Thorp H, Hawayek JA, Atkinson DL, Bartlett CE, Silva FJ, Hsu EW, Moreno AP, Grainger, DW, Patel AN, Evaluation of Multiple Biological Therapies for Ischemic Cardiac Disease, Cell Transplant. 2016 May 10. [Epub ahead of print]. PMID: 27165370. 190. M. Abou-El-Enein, G.N. Duda, E. Gruskin, D.W. Grainger, “Strategies for De-Risking Translational Processes in Biomedical Science and Technology,” Trends Biotechnol., 35(2):100-108 (2016); doi: 10.1016/j.tibtech.2016.07.007. 191. K.Z. Meidell, R. Robinson, A.V. de Abreu, A.J. Gormley, H. Ghandehari, D.W. Grainger, R. Campbell, “RGDfK-functionalized gold nanorods bind only to activated platelets,” J. Biomed. Mater. Res., A. 2017 Jan;105(1):209-217; doi: 10.1002/jbm.a.35902; PMID: 27648522. 192. D. Diekjürgen, D.W. Grainger, “Polysaccharide matrices used in 3D in vitro cell culture systems, Biomaterials, (2017) 141, 96-115; DOI:0142-9612, https://doi.org/10.1016/j.biomaterials.2017.06.020. 193. J. L. Falconer, D.W. Grainger, “In Vivo Evaluation of Silver Nanoparticle and Silver Ion Transport after Intranasal Delivery in Mice,” J. Controlled Rel., 269, 1-9. 2017. 194. J.L. Falconer, J. Alt., D.W. Grainger, “Comparing ex vivo and in vitro translocation of silver nanoparticles and ions through human nasal epithelium,“ Biomaterials, 2018 Jul;171:97-106. doi: 10.1016/j.biomaterials.2018.04.013. Epub 2018 Apr 14. 195. A. Fortunato, D.W. Grainger, M Abou-El-Enein, “Enhancing patient-level clinical data access to improve trial outcomes, promote evidence-based practice and incentivize therapeutic innovation,” Adv. Drug Del. Rev., Published online January 31, 2018. https://doi.org/10.1016/j.addr.2018.01.017. 196. M. Abou-El-Enein, D.W. Grainger, S. Kili, “Registry contributions to strengthening cell and gene therapeutic evidence”, Cell Molec. Therap., in press, 2018. https://doi.org/10.1016/j.ymthe.2018.04.007 197. D. Diekjürgen, D.W. Grainger, “Drug transporter expression profiling in a three-dimensional kidney proximal tubule in vitro nephrotoxicity model”, Pflugers Archiv - Eur J. Physiol., 470(9), 1311-1323. DOI: 10.1007/s00424-018-2150-z. 198. D. Diekjürgen, D.W. Grainger, “An Ex Vivo 3D Kidney Proximal Tubule Nephrotoxicity Model to Better Predict Drug-Induced Epithelial Nephropathy”, Archiv Toxicol, submitted, 2018. 199. K. Sinclair, Z. Farrell, D.W. Grainger, "Antibiotic-Eluting Resorbable Bone Void Filler Evaluated in a Large Animal Infection Model", Eur Cells Mater., submitted, 2018. 200. D. Diekjürgen, K. Kurtzeborn, K. Ngo, N. Balasubramanian, D.W. Grainger, A.E. Brooks, Recombinant Major Ampullate Spidroin 2 (MaSp2) silk protein modified with a heparin-binding motif, Macromol. Biosci., 2018. In revision. 201. H.J. Busscher, V. Alt, H.C. van der Mei, W. Zimmerli, T.F. Moriarty, J. Parvizi, G. Schmidmaier, M.J. Raschke, T. Gehrke, R. Bayston, L.M. Baddour, L.C. Winterton, R.O. Darouiche, D.W. Grainger “A plea for facilitating the Clinical Translation of Antimicrobial Combination Devices”, submitted, 2018. 202. C. Jones, D.J. Holt, A. Brooks, B. Brooks, D.W. Grainger, “Nanoparticles interact with endotoxin and confound assay quantitation in vitro”, under revision, 2018. 203. L. Gamble, D.H. Radford, D.A. Fischer, D.G. Castner, D.W. Grainger, "Quantitative Evaluation of Perfluorinated Alkylthiol Molecular Order on Gold Surfaces", in preparation, 2018.

BOOK CHAPTERS CONTRIBUTED:

1. M. Avula, A. Rao, D.W. Grainger, “Biomaterials in Continuous Glucose Sensing In vivo”, in 2nd edition, Comprehensive Biomaterials eds. P. Ducheyne, K. Healy, D.W. Grainger, J. Kirkpatrick, D. Hutmacher, Elsevier, Amsterdam, 2017. ISBN 9780081006917 2. J.L. Falconer, D.W. Grainger, “Silver-containing Biomaterials”, in 2nd edition, Comprehensive Biomaterials eds. P. Ducheyne, K. Healy, D.W. Grainger, J. Kirkpatrick, D. Hutmacher, Elsevier, Amsterdam, 2017. ISBN 9780081006917 3. F. Liu, D.W. Grainger, “Fluorinated Biomaterials” in 2nd edition, Comprehensive Biomaterials eds. P. Ducheyne, K. Healy, D.W. Grainger, J. Kirkpatrick, D. Hutmacher, Elsevier, Amsterdam, 2017. ISBN 9780081006917 4. D.G. Castner, D.W. Grainger, “Surface analytical methods: in situ and UHV techniques” in 2nd edition, Comprehensive Biomaterials eds. P. Ducheyne, K. Healy, D.W. Grainger, J. Kirkpatrick, D. Hutmacher, Elsevier, Amsterdam, 2017. ISBN 9780081006917 5. C.F Jones, D.G. Castner, D.W. Grainger, “Surface Adsorbates on Nanomaterials and Their Possible Roles in Host Inflammatory and Toxicological Processing,” Chapter 6 in Handbook of Immunological Properties of Engineered Nanomaterials (Volume 1: Key Considerations for Nanoparticle Characterization Prior to Immunotoxicity Studies), 2nd ed., (M. Dubrovolaskia, S. McNeil, eds.), World Scientific Press, Singapore, ISBN: 978-981-4699-16-7. 2016, pp. 376. 6. A. Rao, M.N. Avula, D.W. Grainger, “Aging and the host response to implanted biomaterials,” Chapter 11 in Host Response to Biomaterials, in S. Badylak, ed., Elsevier, Amsterdam, ISBN: 978-0-12-800196-7; 2015, pp. 269-303. 7. M.N. Avula, D.W. Grainger, “Addressing medical device challenges with drug/device combinations,” Chapter 3, in Drug-Device Combinations for Chronic Diseases, R. Siegel., S.P. Lyu, eds., Wiley, New York, ISBN: 978-1-118-12000-2, 280 pp., 2015. 8. C.F. Jones, D.G. Castner, D.W. Grainger, “Surface Adsorbate Processing on Nanomaterials and their possible role in Host Immune and Toxicological Processing”, Chapter 5 in Immunological properties of engineered nanomaterials, (M. Dubrovolaskia, S. McNeil, eds.), World Scientific Press, Singapore, 2013, pp. 117-143; DOI 10.1142/9789814390262_0005. 9. C-Y Lee, L.J. Gamble, G.M. Harbers, P. Gong, D.W. Grainger, D.G. Castner, “Multi-technique characterization of DNA-modified surfaces for biosensing and diagnostic applications” (Chapter 11) in “Surface Analysis and Techniques in Biology”, ed. V. S. Smentkowski, Springer AG, London, (2013), pp. 289-314; DOI 10.1007/978-3-319-01360-2. 10. B. Brooks, A. Brooks. D.W. Grainger, “Antimicrobial Technologies in Preclinical and Clinical Medical Devices”, Chapter 13 in Biomaterials Associated Infection: Immunological Aspects and Antimicrobial Strategies, T. F. Moriarty, S.A.J. Zaat, H. Busscher, eds., Springer Verlag, New York, 2012, pp. 307-354; ISBN 978-1-4614-1030-0. 11. F. Liu, D.W. Grainger, “Fluorinated Biomaterials” in Biomaterials Science, 3rd ed., B.D. Ratner, A.S. Hoffman, J. Lemons, F. Schoen, eds., Academic Elsevier, Amsterdam, 2013, pp. 92-103 (Chapter 1.1.2c) ISBN-10: 0123746264, ISBN-13: 978-0123746269. 12. A. Nel, D.W. Grainger, P.J. Alvarez, S. Badesha, V. Castranova, M. Ferrari, H. Godwin, P. Grodzinski, J. Morris, N. Savage, N. Scott, M. Wiesner, “Nanotechnology Environmental, Health, and Safety Issues,” Chapter 4 in: Nanotechnology Research Directions for Societal Needs in 2020: Retrospective and Outlook (M.C. Roco, C.A. Mirkin, M.C. Hersam, eds.) NSF/WTEC report, 2011, Springer, Boston, USA, pp. 610. 13. F. Liu, D.W. Grainger, “Fluorinated Biomaterials” in Comprehensive Biomaterials vol 1, Chapter 128, eds. P. Ducheyne, K. Healy, D.W. Grainger, J. Kirkpatrick, D. Hutmacher, Elsevier, Amsterdam (ISBN 978-0-08-055302-3), 2011, pp 513-525. 14. D.G. Castner, D.W. Grainger, “Surface analytical methods: in situ and UHV techniques” in Comprehensive Biomaterials – vol 3, chapter 301, eds. P. Ducheyne, K. Healy, D.W. Grainger, J. Kirkpatrick, D. Hutmacher, Elsevier, Amsterdam (ISBN 978-0-08-055302-3), 2011, pp 1-22. 15. D. Holt, D.W. Grainger, “Chapter 6: Host-Implant Response”, in An Introduction to Biomaterials, 2nd ed., (J.O. Hollinger, ed), CRC Press, Boca Raton, FL, ISBN-13: 978-1439812563, (2011). 16. G. Harbers, D.W. Grainger, “Chapter 5: Cell-Materials Interactions: Fundamental Design Issues for Tissue Engineering and Clinical Considerations”, in An Introduction to Biomaterials, 2nd ed. (J.O. Hollinger, ed.), CRC Press, Boca Raton, FL, ISBN-13: 978-1439812563, (2011). 17. J. Veranth, H. Ghandehari, D.W. Grainger, “Nanoparticles in the lung”, in Volume 8 Respiratory Toxicology (G.S. Yost, ed.,), Comprehensive Toxicology series, Elsevier, Oxford, UK, (Chapter 8.23) pp. 453-566 (2010). ISBN 978-0-08-046868-6. 18. M.L. Godek, D.W. Grainger, “The Macrophage in Wound Healing Surrounding Implanted Devices”, in Implantable Glucose Sensing, J. Stenken, D. Cunningham, eds., Wiley, NY, Chapter 2, pp. 18-36, 2009. 19. B. von Rechenberg, L. Meinel, D.W. Grainger, M. Hofman-Amtenbrink, “Introduction to Biotechnology”, in AO Principles of Fracture Management, (2nd ed.), T. Ruedi, ed., AO Publishing, AO Foundation, Davos, Switzerland, pp.47-68, 2007. 20. Gong P, Grainger DW. Nonfouling surfaces: a review of principles and applications for microarray capture assay designs. Methods Mol Biol. 2007;381:59-92. Review. PubMed PMID: 17984514. 21. Grainger DW, Greef CH, Gong P, Lochhead MJ. Current microarray surface chemistries. Methods Mol Biol. 2007;381:37-57. PubMed PMID: 17984513. 22. G. Harbers, D.W. Grainger, “Chapter 3: Cell-Materials Interactions: Fundamental Design Issues for Tissue Engineering and Clinical Considerations”, in An Introduction to Biomaterials, (J.O. Hollinger, S. Guelcher, eds), CRC Press, Boca Raton, FL, pp. 15-45, 2006. 23. Koenig, A.L. and Grainger, D.W., "Cell adhesion-dependent signaling pathways on biomaterials surfaces," Chapter in Biomimetic Materials & Design: Interactive Biointerfacial Strategies, Tissue Engineering and Targeted Drug Delivery, A. Dillow, A. Lowman, eds., Marcel-Dekker, Inc., pp. 187-250, 2002. 24. A.L. Koenig, D.W. Grainger, "Cell Synthetic Surface Interactions: Targeted Cell Adhesion," Chapter 66 in Methods of Tissue Engineering, eds., A. Atala, R. Lanza, Academic Press, NY, pp. 751-770, 2002. 25. D.W. Grainger, C.W. Stewart, “Fluorinated Surfaces, Coatings, and Films: Motivation and Significance”, in Fluorinated Surfaces, Coatings and Films, ACS Symposium Series 787, D.W. Grainger, D.G. Castner, (eds.), ACS Press, 2001. 26. D.W. Grainger, D.G. Castner, (eds.) Fluorinated Surfaces, Coatings and Films, ACS Symposium Series 787, ACS Press, Washington DC, 2001. 27. D.W. Grainger, K. Healy, "Biomaterials Surface Analysis", in Handbook of Biomaterials Evaluation, 2nd ed., A. F. von Recum, ed., MacMillan, NY, 1998 pp 115-141. 28. Y.K. Sung, Y. J. Kim, S.J. Han, D.W. Grainger, T. Okano, S.W. Kim, Surface and bulk compositional characteristics of biomedical hydrophilic-hydrophobic copolymer systems, in Advances in Polymer Biomaterials Science, eds. T. Akaike, T. Okano, M. Akashi, M. Terano, N. Yui, CMC Press, Tokyo, 1997, pp. 231-250. 29. D.W. Grainger, "Polymeric Biomaterials for Surgical Repair of Soft Tissue", in Minimally Invasive Surgery, J. G. Hunter and E. S. Sackier, eds., McGraw-Hill, New York, (1993) pp. 43-55. 30. D.W. Grainger, H. Ringsdorf, "Macromolecular Drug Delivery: A Brief Review of Recent Strategies", in Rhone-Poulenc's Materials of the Future, Paris, 1990.

PROFESSIONAL NEWSLETTER CONTRIBUTIONS:

1. Professional Reviewing: Our Duty Calls, Biomaterials Forum 21(4), 6-7 (2001). 2. Delivery at a Distance: Degradable Ballistic Formulations for Vaccinating Wildlife, Controlled Release Society Newsletter, September, 2005, p. 7. 3. AO’s Biotechnology Advisory Board: Update on AO-sponsored research in biotechnology, AO Dialogue (AO Foundation International newsletter), Vol. 1 (March) 2006. 4. Biotechnology in Musculoskeletal Repair: Outlook and Expectations, AO Dialogue (AO Foundation International newsletter), Vol. 2 (March) 2007. 5. K. Park, Y-H Bae, D.W. Grainger, “Preface: The 13th International Symposium on Recent Advances in Drug Delivery, February 26–28, 2007, Salt Lake City, UT, USA” J. Controlled Rel., doi:10.1016/j.jconrel.2007.07.005; 122(3) 207-208 (2007). 6. “New FOCUS technical programming at the International AVS Symposium, Boston, 2008”, AVS Spring Newsletter, http://www.avs.org, 2008. 7. Park K, Bae YH, Grainger DW. The 14th International Symposium on Recent Advances in Drug Delivery Systems, February 15-18, 2009, Salt Lake City, UT, USA. J. Controlled Rel., 2009 Dec 16;140(3):183-4. Epub 2009 Sep 12. PubMed PMID: 19751779, doi:10.1016/j.jconrel.2009.09.006 8. Park K, Bae YH, Grainger DW, The 15th International Symposium on Recent Advances in Drug Delivery Systems, February 15-18, 2011; This symposium was specially dedicated to the recognition of Sung Wan Kim (USA) and his vast contributions over his career, Preface. J Control Rel. 2011 Oct 30;155(2):113-4. Epub 2011; PMID: 21907741 9. Y.H. Bae, D.W. Grainger, “Preface: The 16th International Symposium on Recent Advances in Drug Delivery, February 3-6, 2013, Salt Lake City, UT, USA”, J. Controlled Rel., 172 393–394; http://dx.doi.org/10.1016/j.jconrel.2013.08.003 10. D.W. Grainger, Y.H. Bae, S.J. Lee, W. Hennink, “Preface: 17th International Symposium on Recent Advances in Drug Delivery, June 14-17, 2015, Salt Lake City, UT, USA”, J. Controlled Release, 220, Part B, 28 569–570 (2015); doi:10.1016/j.jconrel.2015.11.025.

INVITED LECTURES (selected 2017-18, >385 total invited research presentations (international symposia, seminars, talks, conferences) 1990-to date):

 Plenary lecture, “Comparing clinical and preclinical performance of nanomedicines: a disconnect?” European Society for Biomaterials, Maastricht, NL, September 13, 2018.  Invited speaker and session chair, “Analyzing translational barriers in technology transfer”, Biointerfaces International, Zurich, Switzerland, August 15, 2018.  Panel Chair, member, “Barriers to translating biomedical technologies”, Julius Wolff Institute 10th anniversary symposium, Charitë-Berlin, Germany, June 16, 2018.  Invited lecture, “Academic-industrial challenges in biomedical technology translation”, Julius Wolff Institute 10th anniversary symposium, Charitë-Berlin, Germany, June 15, 2018.  Invited lecture, “Antimicrobial Combination Medical Device Translation: Barriers in the University-Industry Translational Ecosystem”, National Materials and Manufacturing Board’s “Roundtable on Biomedical Engineering Materials and Applications”, National Academies, Washington D.C., March 26, 2018.  Invited lecture: “Strategies to immobilize and analyze biomolecules on surfaces”, Chemical Technology, RIKEN Institute, Saitama, Japan, February 7, 2018.  Invited lecture, “Comparing 2D and 3D kidney nephrotoxicity organoid models for drug screening,” TWIns, Tokyo Women’s Medical University, Tokyo, Japan, February 7, 2018.  Invited talk: “Silver nanoparticles: antimicrobial mechanisms and biodistribution in rodents and humans,” CNRS Laboratiore Biomaterieux aux Polymeres, Univ. Paris XIII (Prof. V. Migonney), January 19, 2018.  Invited Tsinghua Xuetang Fellow Lecture, “Chemistry Impacts and Challenges in Modern Medical Technology,” Department of Chemistry, Tsinghua University, Beijing, China, December 5, 2017.  Invited seminar, “Clinical assessment of nanomedicines”, Peking University Medical Center, Beijing, China, December 4, 2017.  Invited special lecturer, “Comparing 2D and 3D kidney nephrotoxicity models for drug screening,” Faculty of Pharmacy, Keio University, Tokyo, Japan, December 1, 2017.  Invited seminar, “Delivery of drugs from surgically implanted devices”, Vanderbilt University, Nov. 1, 2017.  Keynote lecture, “Challenges in clinical translations of nanomedicines”, f-Tales, Univ. Ghent, Belgium. September 21, 2017.  Invited seminar, “Understanding clinical translational failures in nanomedicine”, Department of Bioscience and Biosystems Engineering (D-BSSE), ETH-Zurich (Basel campus), Switzerland, September, 2017  Keynote lecture, “Challenges in antimicrobial device development,” Center for Advanced Studies, Oslo, Norway July 3, 2017.  Invited talk, “Silver as an antimicrobial”, Center for Advanced Studies, Oslo, Norway July 6, 2017.  Invited talk, “Ballistic Bison Vaccines, Biodegradable Bullets and Bison”, Bacterial Biofilms Conference, Stevens Institute of Technology, Hoboken, NJ, June 14, 2017.  Keynote lecture, “Medical Device Translation: Traversing the University-Industry Environment”, CURAM annual site review, National University of Ireland, Galway, April 26, 2017.  Plenary lecture, “Untangling the clinical issues with nanomedicines”, Society for Biomaterials Annual Meeting, Minneapolis, MN, April 7, 2017.  Debate, “Resolved: In vitro test systems can replace animal studies as predictors of human clinical outcomes” Society for Biomaterials Annual Meeting, Minneapolis, MN, April 6, 2017.  Featured Panel Discussion: “Regulatory Science – What is it?” International Biological Engineering Conference, Salt Lake City, UT, March 31, 2017  Keynote Speaker, “Implant performance in a large animal model for addressing periprosthetic infection”, International 10th meeting of the Scandinavian Society for Biomaterials (SCSB), Hafjell, Norway, March 16, 2017.  Invited speaker, “Medical Device Translation: Traversing the University-Industry Environment”, EPSRC-Univ. Nottingham, U.K., January 18, 2017.

OUTREACH: WORKSHOP/SHORT-COURSE/SUMMER SCHOOL/PUBLIC LAY-SPEAKER  Invited graduate student seminar, “Grand Challenges for Biointerfaces”, Biointerfaces International, Zurich, Switzerland, August 13, 2018.  Invited graduate student seminar, “Clinical experiences with nanomedicine for drug delivery”, Biointerfaces International, Zurich, Switzerland, August 13, 2018.  Invited keynote lecture to 800 people, “From Spokane to a Life Well-Lived”, Spokane Youth Scholars Annual Awards Banquet, Spokane, WA, April 14, 2018.  Invited lecture. University of Utah Research Reproducibility Grand Rounds, “Publishing Pressures and Researcher Productivity”, February 27, 2018.  Invited public lecture: “Science accuracy and reproducibility: heads in the sky or in the sand?”, RIKEN Institute, Saitama, Japan, February 7, 2018.  Invited workshop speaker, “How to write a manuscript: an editor’s assessment”, Beijing University of Chemical Technology, China, December 3, 2017.  Short-course instructor, “Silver as a modern therapeutic”; “Clinical assessment of nanomedicines”, “Oral Delivery of Particle Drugs”, “Combination Devices”, Faculty of Pharmacy, Keio University, Tokyo, Japan, November 28-30, 2017.  Expert panel and moderator, “Translating antimicrobial technologies for clinical use,” Center for Advanced Studies, Oslo, Norway July 7, 2017.  Expert panel: “Addressing the impasse in antimicrobial technology translation,” 4th Stevens Conference on Biofilms, Hoboken, NJ, June 15th, 2017.  Invited lecture, “Device related infections and biomaterials: Is there a connection?”, C.R. Bard Vascular Access, Salt Lake City, UT., June 2, 2017.  “Nanomedicine: What’s in a name?”, NanoTechnology Program Retreat invited speaker, University of Utah, May 8, 2017.  “Research reliability through the eyes of a journal editor”, Utah Research Reproducibility and Reliability Conference, Salt Lake City, UT, November 14, 2016.  “Blood-materials interactions in coronary stenting: a review of fundamentals”, TCT2016 Satellite Symposium, Washington, DC, October 29, 2016.  “Publication ethics”, New Zealand Controlled Release Society Workshop, Auckland, June 1, 2016.  “Funding models in start-up companies”, New Zealand D4 (Drugs Devices, Diagnostics, Development) Student Innovation Workshop, Univ. Otago, Dunedin, New Zealand, May 22, 2016.  “Models for University-Business relations in technology transfer”, Dunedin Chamber of Commerce, Dunedin, New Zealand, May 13, 2016.  “Personal experience with university-business technology transfer”, Dunedin Entrepreneur’s Breakfast meeting, New Zealand, March 13, 2016.  “University inventors: Students, Faculty, and Staff”, Otago Audacious Innovation Programme, Dunedin, New Zealand, March , 2016.  Didactic lecture (90 minutes): ”Hydrogels in Medical applications,” Graduate Biomaterials course, Chalmers University, Sweden, December 9, 2015.  Invited debate: “Biomaterials education is not ready to address future challenges”, International Society of Biomaterials Society Fellows Debate (opponent), European Society for Biomaterials, Krakow, Poland, August 31, 2015.  Invited Panel Discussion: “Barriers to translating biomedical technologies,”, Summer Institute, Center for Protection of Intellectual Property, Beaver Creek, CO, July 23, 2015  Invited Panel Discussion: “Translational hurdles for antimicrobial technologies”, 3rd Stevens Institute Bacteria, Biofilms and Biomaterials Conference, Hoboken, NJ, June 18, 2015.  Invited debate: “Translational research is more impactful than basic research”, International Society of Biomaterials Society Fellows Debate (proponent), Society for Biomaterials, Charlotte, NC April 17, 2015.  Invited Panel discussant, “Antimicrobial technology translational challenges: the regulatory hurdles”; U.S. Food and Drug Administration/CBE Workshop on Antimicrobial Devices, MD, February 11, 2015.  Invited lecture, CME short course, The 58th Annual Edward T. Smith Orthopaedic Lectures, “Demineralized Matrix use in Orthopaedics, University of Texas-Houston, Department of Orthopaedic Surgery, November 14, 2014.  Invited Forum discussion coordinator, “Downward translation of antimicrobial technologies”, 5th Thesinge Biofilms Conference, Groningen, The Netherlands, September 9, 2014.  Invited lecture: “Write that grant! Translational Research Support Strategies for Clinical Pharmacists”, AACP Research Workshop, Grapevine, TX, July 26, 2014.  Invited speaker: “Addressing the barriers to ocular delivery”, Controlled Release Society Ocular Workshop, Chicago, July 15, 2014.  “Utah’s history with the artificial heart”, Alta Club monthly lecture, Salt Lake City, April 17, 2014  “Challenges of Educational Leadership”, University of Utah Leadership Forum panel, November, 2013  “Writing your manuscript: best practices”, Tsukuba International Conference on Materials Science Biomaterials Summer School, Tsukuba, Japan, August 28, 2013.  “Barriers to oral absorption of nanotechnologies”, Global Pharmaceutics Education Network Biennial Meeting workshop, November 27, 2012, Melbourne, Australia  Panel chair, Theme: “The Future of Nanomedicine”, Second International Symposium on Polymer in Controlled Delivery, Suzhou, China, September 12-14, 2012.  Mentor and Panelist, NIH/CSR Scientific Review Group Chair’s Orientation, National Institutes of Health, Center for Scientific Review, Bethesda, MD, August 30-31, 2012.  Session panelist: Nanomaterials characterization workshop, Greener Nano 2012, Portland, OR, July 30, 2012  “Scientific publication ethics: best practices”, Institute for Biomedicine, University of Basel, Switzerland, June 22, 2012.  “How to give an effective presentation”, SIMS2012 student workshop, University of Tsukuba, Japan, March 17, 2012.  “Nanotechnology and Nanomedicine, University of Utah Health Science Advocates presentation, January 24, 2012, Salt Lake City, UT.  “Pharmacokinetics of nanoparticle oral uptake and systemic biodistribution,” Joint NIH and USDA Workshop on Using Nanotechnology To Improve Nutrition Through Enhanced Bioavailability and Efficacy, November 29-30, 2011, Bethesda, MD.  “The elephant in the nano-room”, Utah Nanotechnology Graduate Training, and Nanobiosensors, Nanomaterials and Microfluidics NSF IGERT program joint retreat, invited lecture, October, 2011.  “Understanding interactions of nanotechnology in the human body”, Global Center of Excellence International Student Education Program, Kyushu University, Fukuoka, Japan, October 16, 2011.  “Writing and reviewing scientific papers: best practices,” 5th International Chinese Pharmaceutical Society student workshop, Shanghai, China, October 14, 2011.  “Innovations in implant surface technologies”, Orthopedic Trauma Association Resident Basic Science Workshop, San Antonio, TX, October 12, 2011.  “Nanotechnology interactions with human tissues”, Brandenburg Summer School on Regenerative Therapies, Berlin, Germany, August 25, 2011.  “Combination devices as new medical technology”, Chinese Association of Science and Technology, Utah Chapter Annual meeting, Salt Lake City, UT, February 27, 2011.  “Knowledge and technology transfer at University of Utah”, Hangzhou Science and Technology Development Agency, Hangzhou, China, November 2, 2010.  “Biomaterials infections: what you need to know”, Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, October 20, 2010.  “Bio-immobilization and adsorption of biomolecules at surfaces”, 3 lectures, EU graduate course, Technical University-Denmark, Lyngby, Denmark, September 1-2, 2010.  “Addressing the trifecta of implant-centered infection contributors”, AOTrauma, AO Foundation’s Bone implant infection workshop, Boston, MA, July 23, 2010.  “Biodistribution of nanotechnology”, NSF/NNI National Consensus Workshop, Chicago, March, 2010.  “Combination Devices as a Way of the Future”, Department of Orthopedics Grand Rounds, University of Utah, November 3, 2009.  “Personalized Medicine in Utah”, Emeritus Alumni Association of the University of Utah, Annual Dinner speaker, September 23, 2009, UT  “Surface engineering strategies for improving diagnostics”, CCMX/ESB Workshop on surface engineering in biomedical applications, September 9, 2009, Lausanne, Switzerland.  “Models for studying foreign body responses”, Madame Curie European Union Post-Graduate Course in Biomaterials, August 23, 2009, Aachen, Germany.  “Medical device failure: What can we learn?”, Madame Curie European Union Post-Graduate Course in Biomaterials, August 23, 2009, Aachen, Germany.  “Personalized medicine: near-term opportunities”, Personalized Health Interest group, Univ. Utah, March, 2009  “Personalized medicine’s meaning for you”, Park City Institute, Park City, UT, March 24, 2009  “Foreign body responses to implanted materials,” AO BAB-CAN Biotechnology workshop, Toronto, Canada, April 6, 2008.  “Bridging the Gap: Translational Research Support Strategies for Clinical Pharmacists”, ACCP National Young Investigator Workshop, Salt Lake City, UT, July 12, 2008  “Biomedical materials and host response: why can’t the body integrate devices? Biomedical Engineering Undergraduate Club, University of Utah, March, 2008.  KUER Public Radio “Science in Society series”: “Fluorine and the Public” panel speech, February, 2007  “Emerging opportunities in biomaterials,” ACS Regional Division monthly speaker, April, 2005.  Society for Manufacturing Engineering Continuing Education short-course instructor, theme: “biomaterials”, multiple courses, 2004-2006.  “Cell signaling assays”, NATO Biomaterials Summer School, July, 2004, Linkorping, Sweden  “Tissue engineering methods”, NATO Biomaterials Summer School, July, 2004, Linkorping, Sweden.

Public media/Outreach: 1. Invited William Evans public lecture, “The Replaceable You: Medical Parts, Problems, and Possibilities,” University of Otago, Dunedin, New Zealand, October 21, 2015. 2. KUED Public Radio “Science in the Public Eye” Forum, “Fluorine and You” public discussion panel participant, October, 2006 3. Featured reviewer, panelist and interview, National Institutes of Health’s Center for Scientific Review Mock Study Section professional instructional video participant, October, 2009 (posted to http://www.youtube.com/watch?v=HMO3HoLJuJY) (Also http://www.pharmacy.utah.edu/CoP_Information/news/NIH_peer_review_process.html) 4. Featured reviewer, panelist and interview, AO Foundation’s Peer-Review video, September, 2012 (posted to https://www.aofoundation.org/Structure/research/review/Pages/Peer-Review-Process.aspx) 5. University of Utah’s Algorithm publication, featured article “If undergraduates could publish research”, 2012. (also at: http://healthsciences.utah.edu/innovation/) 6. University of Utah feature video on faculty innovation: http://healthsciences.utah.edu/innovation/, 2012. 7. “Update on AO-sponsored research in biotechnology”, AO Dialogue, AO Foundation, Switzerland, 1/2006, pp. 34-37. 8. Research featured in: J. Gorman, Getting out the thorn: Biomaterials become friendlier to the body”, Sci. News, 161 13-15 (2002).

PATENTS (issued and pending):  “Self-Assembling Bound Polymeric Layers on Surfaces”, US patents Nos. 5,686,548 and 5,686,549, issued November 11, 1997; inventors Fang Sun and David W. Grainger; assignee Research Corporation, Tucson, AZ  “Use of Self-Assembling Polymerizable Monolayers to Improve Surface Adhesion to Metals”, US patents filed, 2000; assignee Hewlett-Packard Corporation (now Agilent).  “Synergy between systemic antibiotics and local antibodies in preventing infection”, US Patent application filed, February, 2000; assignee Anthony Gristina Research Institute, VA, USA.  “Hydroxyl functional surface coating” - United States Patent 7501157, Inventors; Guoqiang Mao, Steven W Metzger, Michael J Lochhead, David A Goldberg, Charles H Greef, David W Grainger; Assignee: Accelr8 Technology; Application Date: 2005-01-13; Publication Date: 2009-03-10.  “Electrochemical detection of substrates” US patent 7892816. Inventors: C.M. Elliott (Fort Collins, CO US) Bignozzi, Carlo Alberto (Ferrara, IT) Xue, Di (Fort Collins, CO, USA) Grainger, David W. (Salt Lake City, UT, US) Caramori, Stefano (Ferrara, IT) Dissette, Valeria (Rovigo, IT). File date 09/28/2006; Issue date 02/21/2011. Assignee: Colorado State University Research Foundation. Country: USA.  “Controlled Release tissue graft Combination Biomaterials,” U.S. Provisional Application No. 61/070,638, full utility patent filed March 23, 2009. Inventors; Bruce G Evans; David Christopher Evans; Paul C Hogrebe; David W Grainger; Amanda Elaine Brooks, Document Number: US 20090324683, Publication Date: 2009-12-31, assignee: University of Utah; Serial No.: 12/409,261 Notice of Allowance, November 14, 2013.  ”Method for Enhancing Bone Mineralization by Inhibiting Osteoclast Formation and Bone Resorption Using Small Interfering RNAs targeting RANK and Other Bone Resorbing Signaling Pathways,” University of Utah disclosure U-4670, Date: 06/08/2009, Yuwei Wang, David W. Grainger.  “Novel Proteinaceous 3D Scaffolds with Highly Tunable Architecture and Composition for Cell Culture: Medical Device and Tissue Engineering Applications,” University of Utah disclosure U-4642, Date: 04/28/2009, Inventors: Paul C. Hogrebe, David W. Grainger, Amanda E. Brooks, Dolly J. Holt.  “A Biodegradable, Bilayer Perivascular Wrap for Directed Agent Delivery", University of Utah Invention disclosure (NIH grant no. R01 HL067646, C. Terry, PI), 2010, D.W. Grainger, W. Sanders, C. Terry, P. Hogrebe; abandoned.  U.S. Provisional Patent Application No. 61/543,089 (filing date: October 4, 2011, University of Utah Invention Disclosure U-5044 “Method to improve implanted biomedical device performance by delaying the host foreign body response”, Mahender Avula, Archana Rao, David Grainger, Florian Solzbacher; June 30, 2011.  “Tissue Fixation”, United States Patent Application No. 12/783,507, Erik N. Kubiak, Emmon J. Chen, David W. Grainger. filed May 19, 2010, US20110288565 A1, WO2011146765A1.  “Drug Release from a Polymer-Controlled Local Antibiotic Delivery System Using a Degradable Bone Graft”, A. Brooks, B.D. Brooks, D.W. Grainger, U.S. provisional application 61/761,086, February 2013. Abandoned, 2013.  U.S. Patent Application “Controlled Release Tissue Graft Combination Biomaterials” Serial No. 12/409,261 B. Evans, D.C. Evans, P. Hogrebe, A. Brooks, D.W. Grainger, filed, March 23, 2009. US patent 8,685,432 granted, 4/1/2014.  “Tissue Fixation” United States Patent Application No. 14/576,814, E.N. Kubiak, E. J. Chen, D.W. Grainger, filed December 10, 2014.  U.S. Patent US 9,889,235 B2, “Implantable Devices for Bone or Joint Defects”, Amanda Brooks, David Grainger, Kristofer D. Sinclair, Benjamin Brooks, February 13, 2018.  (Also assisted, authored and consulted on several industrial patent applications)

EXTRAMURAL RESEARCH SUPPORT (Confidential): (~$22 million in extramural funding to date)

Current:

USTAR UTAG (State of Utah 3/2017-9/2018) P.I. D.W. Grainger Human cell sheets as allogenic therapies in regenerative medicine Overall goals: demonstrate preclinical proof of concept for human stem cell lines in therapeutic cell sheet applications for regenerative medicine in cardiac patch and cartilage regeneration. Grainger 8% effort as PI.

NIH R01 EB018092 (09-01-2014-08/31-2019) PI: H. Ghandehari Biological Fate and Biocompatibility of Dendritic and Silica-Based Nanoconstructs Overall goals: continue to ascertain toxicity mechanisms and biodistribution for silica-based nanoparticles as a function of shape and size, and surface properties. Correlation of dosing, in vitro and in vivo toxicity mechanisms is a primary deliverable. Grainger as co-I has 5% annualized effort (0.60 person months) in Years 3-5 only.

Pending:

Inflammatory Cytokine Modulation to Prevent Post-Traumatic Osteoarthritis (July 1, 2018-June 39, 2021) co-PIs: J.A. Haller, T. Higgins, D.W. Grainger Congressionally Directed Medical Research Programs (Peer Reviewed Medical Research Program, PRMRP), Defense Health Agency Overall goal: correlation of acute injury biomarkers to predict onset of post-traumatic osteoarthritis (PTOA) and pharmacological mitigation of acute inflammatory biomarkers to prevent PTOA. 12.5% annualized effort, 3 years Sponsor: Department of Defense

COMPLETED

NIH R01EB011879 (07/01/2010-05/31/2014) PI: D.W. Grainger Foreign Body Response as a Performance Metric for Implanted Scaffolds Overall Goals: In Vivo Characterization and Modulation of Wound Healing for Novel Proteinaceous Porous Scaffolds and Coatings in the Context of the In Vivo Implant FBR. 11% annualized effort Sponsor: National Institutes of Health

Astra-Zeneca, Inc. research contract (9/1/2013-8/31/2015) PI: D.W. Grainger Mutant mouse models for drug nephrotoxicity screening Overall goals: exploit commercial mouse models of nephrotoxicity testing in high throughput screens 11% annualized effort

NIH R01 DK100505 (08/07/2014-07/31/2018) PI: Y-T Shiu Mechanotransduction in Neointimal Hyperplasia Formation in Arteriovenous Grafts Overall Goals: This project will characterize fluid shear stress and wall circumferential stress in arteriovenous grafts in a porcine model, and investigate the roles of mechanosensative transcription factors and signaling molecules (with a focus on the receptor tyrosine kinase and Ets-1 signaling pathway) in the formation of neointimal hyperplasia in arteriovenous grafts. $217,500/year: Grainger as co-I has 5% annualized effort in Year 1 only Sponsor: National Institutes of Health

NIH 2R01EB001473 (05/01/2009 - 04/30/2012) PI: Grainger, D.W. Title DNA Microarray Surface Analysis to Optimize Detection Overall goals: application and development of high-resolution surface chemistry analytical methods to describe DNA immobilization at surfaces relevant to microarray assays, and to correlate several ultra-sensitive DNA density and conformational measurements to the clinically common fluorescent read-outs for these assays in genomics. % FTE Effort PI: 11% Sponsor: National Institutes of Health

NIH 5R01HD061014 (03/15/2009 – 02/28/2013) Bachus, K., (PI), Grainger, D.W., (co-PI) Infection-Prevention Barriers for Osseointegrated Percutaneous Implants Overall Goals: innovation of metal/polymer percutaneous devices fixed directly to amputee bone that encourage tissue in-growth, healing and thereby prevent implant-centered infections while encouraging mechanical stabilization. % FTE effort: 11% Sponsor: National Institutes of Health

University of Utah Technology Commercialization grant (10/2009-11/2010) PI: Grainger, D.W. Development Of A Novel Antibiotic Eluting Bone Graft Goals: To develop a new anti-infective surgical orthopaedic bone graft biomaterial that releases antibiotics over 6-8 weeks for trauma, revision surgeries and major repairs. % FTE effort: 5% (non-compensated) Sponsor: University of Utah

NIH 1R21DK088426 (April, 2010-March, 2012) PI: Grainger, D.W. A Novel Self-Renewing Heparin-Binding Anti-microbial Device Surface Coating Overall goals: use of spider silk-based recombinant protein cassettes to include heparin-binding capabilities for use a new anti-coagulant, anti-infective device coating for in-dwelling catheters in blood. % FTE effort: 5% Sponsor: National Institutes of Health

NIH 1R01EB001473 (7/2003-6/2008) PI: Grainger, D.W. DNA Microarray Surface Analysis to Optimize Detection Total award amount: $1,800,000 (Total direct) % FTE effort: 11% Sponsor: National Institutes of Health

NIH 1R01EB000894 (January, 2003 – April, 2008) PI: D.W. Grainger Validating Macrophage Foreign Body Inflammatory Response Goals: to determine and compare monocyte.macrophage phenotypes in vitro on model biomaterials surfaces for secondary commercial cell lines versus primary harvested macrophages and correlate these phenotypes with the host foreign body inflammatory reactions in vivo. Total award amount: $1,300,000 (total direct costs) % FTE effort: 11% Sponsor: National Institutes of Health

Industrial, Commercial Technology Translation, and Consulting:  Scientific Advisory Board, EndoShape, Inc., (shape memory polymer medical devices) Denver, CO  Scientific Advisory Board, Elute, Inc, (drug controlled-release bone grafts), Salt Lake City, UT  Scientific Advisory Board, ConusRx (pain therapeutics) Salt Lake City, UT  Scientific Advisory Board Foldax, Inc, (heart valve technology) Salt Lake City, UT  Past Scientific Advisory Board, Semprus, Inc. (now Teleflex, anti-microbial polymers), Cambridge, MA  Past Scientific Advisory Board, Accelr8 Technologies (AST), Denver, CO  Past Scientific Advisory Board, CellSeed, Inc., (tissue engineering products), Tokyo, Japan  Past Scientific Advisory Board, Photokinetic Coatings (photochemical thin films), Ogden, UT  Past Scientific Advisory Board, Synthes, Inc, USA (now DePuy/J&J Orthopedics), Paoli, PA  Former consultancies: 3M, iSense, Becton Dickinson, Agilent, CibaVision, Cobe Medical, Catheter Connections, CellSeed, Ltd (Japan)  Numerous contracted consulting activities, research grants and contracts from industry  Patent evaluation and medical device testing regulatory document preparation